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ABSTRACT 
In Paper I a method for sample preparation of urinary proteins was developed and optimized. 
The main steps were desalting/enrichment by cut-off centrifugation (5 kDa), albumin 
depletion and tryptic digestion followed by 2D-LC-MS. Emphasize was put on maximizing 
protein recovery and improving downstream compatibility. A 2D-separation approach 
combining ZIC-HILIC and RP was also tested and gave a separation system with a high 
degree of orthogonality. Finally, the suitability of the method was assessed in a 
comprehensive proteomic experiment using urine from renal transplants. A high number of 
urinary proteins were identified and the variability of the whole method was in the range of 
11 to 30 % (RSD). 
 
In Paper II enzymatic digestion using immobilized trypsin beads was investigated. 
Evaluation of different reactor formats and conditions like digestion temperature and reaction 
time were carried out to find the optimum setup. Larger proteins demanded longer digestion 
time and BSA was digested in 89 minutes at 37 °C. The optimized procedure was compared 
with digestion in-solution with respect to time consumption, sequence coverage and degree of 
unsuccessful cleaving. The final digestion set-up was carried out in urine samples yielding 
good signal intensities and reproducibility.  
 
In Paper III a multidimensional on-line system including Strong Anion Exchange 
Chromatography (SAX) separation of native proteins, reduction, alkylation, C4 separation 
and tryptic digestion of the alkylated proteins followed by MS detection was tested as an 
alternative to the off-line method developed. Proof of concept was shown and the efficiency 
of the reduction and alkylation was equivalent with established methods. On-line tryptic 
digestion was satisfactory for several proteins but needs further optimization to cover the full 
proteome. The system was evaluated using both model proteins and human urine sample and 
has shown potential as a tool to identify biomarkers offering short analysis time and 
minimum manual sample handling. 
 
In Paper IV proteolytic 18O-labeling of peptides was investigated and improved in order to 
optimize the labeling efficiency and accelerate the process. Optimization was carried out 
using BSA and cyt c as model proteins and the best efficiency was achieved at pH 6 yielding 
  
complete labeling during 2 hours at 37 °C with immobilized trypsin beads. An approach 
integrating tryptic digestion developed in Paper II with 18O-labeling, both using immobilized 
trypsin beads was also developed. This enabled tryptic digestion and 18O-labeling by 3.5 
hours, without any sample transfer steps. The procedure was evaluated in urine, first by 
spiking it with model proteins and then by analyzing the true human urinary proteome after 
implementation in the workflow developed in Paper I.  
 
In Paper V the method developed in Paper I, II and IV was used to identify urinary proteins 
associated with acute rejection episodes in kidney transplanted patients. A large degree of 
regulation was found and 11 proteins were identified as up-regulated in the rejection group 
(n=6) compared with the control group (n=6) according to strict criteria. The up-regulated 
proteins could be grouped by biological function in 2 main groups; proteins involved in 
growth and proteins involved in immune response. The growth proteins were statistically 
significantly up-regulated (P=0.03) while the immune proteins only showed an overall trend 
towards up-regulation in the rejection group compared with the control group (P=0.13).  
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1 Introduction 
Solid organ transplantation is a unique treatment option for organ failure where the failing 
organ function is replaced by organs obtained from either a living or deceased donor. The 
organs most frequently transplanted are; kidney, heart, lungs and liver. Most of the 
transplants are performed between genetically non-identical individuals, where the immune 
response of the recipient against the foreign graft is one of the principal obstacles to a 
successful transplantation. This immune response is generally referred to as a rejection. 
Acute rejection (AR), which is subcategory, predominately appears the first 3 months post-
transplant, but can also emerge after several years. All patients are treated with a cocktail 
of immunosuppressive drugs to inhibit the immune reaction. This is usually a lifelong 
treatment. In order to control this immune response, serotyping is performed to determine 
the best donor/recipient (antigen) match possible. 
Transplanted patients need to be continuously monitored for immune activation and 
acute rejections, especially during the early phase after transplantation. Currently, acute 
rejection episodes are suspected upon sudden decrease in renal function, without other 
plausible explanation, and verified by kidney biopsies. Raised plasma creatinine levels as 
an indicator of AR is neither specific nor sensitive and might as well reflect other 
diagnosis, e.g. drug toxicity (cyclosporine A, CsA). A molecular biomarker (in this case, a 
protein), which could be used to diagnose AR more selectively and ideally at an earlier 
stage, would be of great value to improve the monitoring of these patients. Relevant 
adjustments of the immunotherapy could then be introduced earlier enough to possibly 
reverse the initiating AR and potentially avoid the use of highly toxic anti-rejection 
therapy.  
Urine is one of the most attractive sources for biomarker search due to the non-
invasive sampling procedure. The protein concentration in urine of healthy subjects is low 
(less than 100 mg/L) compared to other body fluids. Despite this, urinary proteomics 
seems very promising in the search for biomarkers and is a rapid growing field [1]. About 
30 % of the proteins in urine originate from plasma while the remaining 70 % originate 
from the kidney [1,2]. Urine may therefore provide specific advantages for detection of 
local effects within the kidney, but also other functions of the body can be monitored since 
a large part of the urinary proteome derive from plasma. Recent development in the field of 
mass spectrometry and bioinformatics along with the DNA sequencing elucidating the 
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human genome has offered great possibilities to analyze the proteome of different body 
fluids.  
 
1.1 Kidney transplantation 
1.1.1 Kidney transplantation in general and the status in Norway 
Renal transplantation is the ultimate renal replacement therapy (RRT) for most patients 
with end-stage kidney disease [3]. Genetic similarity to the recipient makes living relatives 
favorable donors, but since 1984 unrelated living donors have also been used. If no 
acceptable living donors are available, a good alternative is deceased donors. In Norway, 
all transplantation is performed at Oslo University Hospital (Rikshospitalet) where each 
renal transplant recipient is followed closely for about 3 months before they are transferred 
to their respective local nephrology center. The patients in the current study were in the 
early post-transplant phase and thus followed clinically at Rikshospitalet. 
The last few years there has been a slight increase in number of transplantations in 
Norway and in 2009 a total of 292 renal transplants were performed at Rikshospitalet, 
which was a new all-time high [4]. Among these, 38 % of the patients received grafts from 
a living donor and 62 % from a deceased donor and 248 (92 LD and 156 DD) of these 
transplantations where the first transplant for the recipients. The mean age of the recipients 
from living donors were 46.9 years (range 1-78) while for those receiving from deceased 
donors the mean age was 57 years (range 14-80). The primary renal diseases which most 
frequently resulted in need of RRT were the following; vascular/hypertensive nephropathy 
(32 %), diabetic nephropathy (18 %) and glomerulonephritis (17 %) [4]. The graft and also 
patient survival has increased markedly the last 30 years. This is related to major changes 
in immunosuppressive therapy where especially the introduction of CsA based 
immunotherapy in 1983 improved survival. The observed two-year patient survival was 84 
% for patients transplanted in the period of 2000-2004 while the five-year survival was 
approximately 70 % for the same group [5]. 
The basis immunosuppressive protocol at the hospital has since 2007 been 
quadruple treatment. This treatment includes mycophenolate, steroids, low dose 
calcineurin inhibitor (CsA or tacrolimus depending on several criteria e.g. age) in addition 
to induction therapy with i.v. basiliximab at the time of transplantation.  
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1.1.2 Acute rejections 
Cause 
Acute rejection is a serious and relative frequent complication after renal transplantation 
affecting long-term graft outcome. The allograft rejection is caused by several elements of 
the immune system including antibody, complement, T-cells and other cell types [6]. 
Mechanisms believed to be responsible are thoroughly reviewed by Cornell et al. [7], see 
Figure 1 for cells and mediators involved. T-cell-mediated acute rejection is characterized 
by accumulation of mononuclear cells (mostly T-cells) in the interstitium, accompanied by 
inflammation of tubules and sometimes arteries. Another variant of acute rejection is 
antibody-mediated rejection, differentiated by the presence of alloantibodies [8]. The 
pathology has however a wide spectrum and could also include a component of acute 
cellular rejection. In contrast to T-cell-mediated rejection, the alloantibodies preferentially 
attack the peritubular and glomerular capillaries, where accumulation of neutrophils and 
monocytes occur [8]. 
  
 
Figure 1. Overview of cells and mediators involved in acute rejection (from reference [6] 
with permission). 
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Diagnosis 
Examination of immunological activity by histological analysis in renal biopsies is 
currently the gold standard for diagnosis of acute rejection episodes. This is carried out on 
suspicion of acute rejection, often made on basis of clinical symptoms of impaired renal 
function (elevated plasma creatinine levels). One of the challenges is that CsA and 
tacrolimus can give the same symptoms, but then as a result of high dosage. Paradoxically, 
increased plasma creatinine can thus be observed as a consequence of both over- and 
under-immunosuppression. The biopsies are classified according to the Banff criteria, 
which is a standardization of renal allograft biopsy interpretation based on international 
consensus. Classification is performed by using a scoring system determining type and 
severity of the AR and in the current study (Paper V), the Banff 97 criteria were used [9]. 
Antibody-mediated rejection type is identified by positive C4d staining in addition to other 
criteria [8].  
 
Effect on outcome 
The event of AR in renal transplants increases the risk of developing chronic allograft 
nephropathy and is also associated with reduced long-term survival [10-14]. Several 
factors including the timing and severity of the acute rejection episode and the post 
rejection recovery of renal function affects the chronic allograft injury [15-17]. Antibody-
mediated rejections generally has worse prognosis and demands a different form of therapy 
than the usual T-cell-mediated rejection [8]. 
 
1.2 Proteomics 
The proteome can be described as the protein complement of the expressed genome, 
including protein modifications occurring during and after translation [18]. Proteomics is 
the study of protein properties like expression levels, post-translational modifications, 
interactions etc. on a large scale to obtain a view of disease processes, cellular processes 
and networks at the protein level [19]. Detection of proteins using mass spectrometry (MS) 
can either be done by a top-down approach where intact proteins are analyzed or by a 
bottom-up approach where proteins are digested into smaller peptides prior to analysis. In 
this thesis, a bottom-up approach has been applied; the principal workflow is presented in 
Figure 2. As discussed more thoroughly in section 1.2.3, the bottom-up approach benefits 
from better mass detection and sensitivity of the resulting peptides compared with intact 
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proteins which are analyzed when using a top-down approach. The main steps, presented 
in the following sections, are sample preparation to isolate the proteins of interest from the 
matrix followed by digestion of the proteins into peptides using a specific protease with 
known digestion pattern. Further, the peptides are separated and detected by liquid 
chromatography coupled to MS. In addition, a quantification strategy has to be 
implemented somewhere in the workflow depending on the approach chosen. Finally, 
processing of the large amounts of data obtained is an essential part of the work in order to 
identify and quantify proteins. 
 
Urine
Centrifugation
Protein enrichment
Centrifugal filtration 5 kDa cut-off
(Vivascience)
HSA removal
Vivapure
Tryptic digestion
1st dimension LC
ZIC®-HILIC
LC-MS/MS
LTQ-Orbitrap
30 fractions
18O/16O-labeling
Protein identification
Quantification  
Figure 2. The main steps of the workflow developed in this thesis 
 
1.2.1 Sample preparation in urinary proteomics 
Urine is a less complex matrix than for instance plasma, especially with respect to protein 
content, but still requires sample preparation in order to obtain data of good quality from 
the LC-MS/MS analysis. Since the protein concentration in urine is relatively low, 
effective protein enrichment is advantageous in the sample preparation. Nevertheless, this 
should not be at the expense of high and repeatable protein recoveries to cover the whole 
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proteome and to ensure confident assessment of differential expressed proteins observed. 
In addition to this, the salt concentration in urine can be a challenge with regard to both 
LC-MS and gel electrophoresis, thus making effective desalting vital in the sample 
preparation. Several sample preparation methods have previously been described in the 
literature [20-23]. The methods evaluated include precipitation using different agents (e.g. 
organic solvents), lyophilization, ultracentrifugation and molecular weight cut-off 
centrifugation where both protein recoveries and the quality of the protein spots (gel 
electrophoresis) have been assessed. In this work, 5 kDa cut-off centrifugation and protein 
precipitation using ethanol and trichloroacetic acid (TCA) have been tested. Ethanol was 
chosen due to the high protein recoveries reported previously [20]. TCA and cut-off 
centrifugation were included to be able to compare different enrichment principles. 
 The dynamic range of protein concentrations in body fluids span several orders of 
magnitude, up to 1011-1012 in plasma [24,25]. The most valuable information, however, 
probably lies in the low abundant segment of the proteome and this is easily overshadowed 
by high abundant proteins like albumin and immunoglobulins [26]. Thus, depletion of 
proteins has become a standard approach for in-depth analysis of the proteome. Although 
depletion pretreatment could affect the recovery negatively and has shown to co-deplete 
other proteins, it has also been demonstrated to increase the total number of proteins 
identified [22,27]. In the case of urine some reports suggest that the problem with large 
dynamic range is not as severe as in plasma, and that protein concentrations are more 
evenly distributed [28]. Most depletion strategies are based on immuno-affinity, ranging 
from depletion of only human serum albumin (HSA) up to 20 of the most abundant 
proteins. There is a wide range of commercially available kits for such depletion. 
 
1.2.2 Proteolytic digestion of proteins 
After purification, isolation and enrichment of the proteins, the next step is digestion of 
proteins into peptides. This is an essential step of the bottom-up approach and is done by 
the use of enzymes cutting at specific sites on the protein generating predictable peptides 
of suitable length for the subsequent analysis by mass spectrometry [18,29]. Trypsin is the 
most widely used enzyme for this purpose, cleaving the proteins exclusively at the arginine 
and lysine residues, except when followed by proline [30,31]. This generally leads to 
shorter peptide sequences, which is favorable for MS detection compared with enzymes 
that only cleave at one amino acid residue. Tryptic digestion is usually preceded by 
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reduction and alkylation of the proteins to break the sulfide bridges that are present in most 
(large) proteins. This results in unfolding of the proteins to make the cleavage sites more 
accessible to trypsin, yielding a more efficient digestion. Tryptic digestion has traditionally 
been carried out in-solution, but lately much attention has been paid to digestion using 
immobilized trypsin using different carrier materials and formats [32-35]. There are several 
advantages offered by the use of immobilized trypsin: shorter reaction time, possible re-use 
of the enzyme and improved stability of the enzyme. In addition, the use of immobilized 
trypsin allows for automation as reviewed by Massolini and Calleri [36]. 
 
1.2.3 LC-MS/MS of proteins/peptides 
Analysis of intact proteins demands high resolution MS equipment in order to achieve an 
acceptable mass accuracy in the high mass range where intact proteins are measured [37]. 
Since the mass accuracy is better in the low mass range, analysis of peptides allows for a 
better mass detection. Another drawback, particularly when electrospray ionization (ESI) is 
used, is that the intact proteins becomes multiple charged which reduces the sensitivity 
substantially as opposed to peptide ionization which have far less charge distribution. 
Furthermore, enzymatic cleavage of proteins into peptides increases the overall solubility 
of the sample, which is a clear advantage for the following analysis. 
 
Separation by liquid chromatography 
Separation of proteins has in proteomics routinely been done using two-dimensional gel 
electrophoresis (2-DE) followed by in-gel digestion prior to MS [2,38]. Although valuable 
information for protein identification is obtained (i.e. molecular weight, isoelectric point), 
the method suffers from poor recovery of hydrophobic and large proteins and labor-
intensive operation. An alternative approach is the use of shotgun proteomics, where the 
sample is proteolytically digested in-solution prior to separation that is performed using 
liquid chromatography [39-41]. The challenge with this approach is the massively 
increased sample complexity due to all the peptides originating from a single protein after 
digestion. A reduction of the sample complexity prior to the mass spectrometric detection 
is usually necessary to secure good quality data and satisfying protein identification. To 
achieve this, several peptide separation strategies are often combined to increase the 
number of peptides possible to separate in the system.  
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Peak capacity is a theoretically term often used to describe the numbers of peaks 
(peptides) that can be separated in a separation system. The theoretical peak capacity in a 
2D system is defined as the linear combination of the peak capacity in both dimensions 
[42]. The practical achievable peak capacity will however be limited by the orthogonality 
of the system, which means that if the two dimension of separation are not completely 
orthogonal (dissimilar), the achievable peak capacity is lower than theoretically expected. 
Several two-dimensional liquid chromatography (2D-LC) approaches have been developed 
including the most typical, strong cation exchange chromatography (SCX) coupled to RP, 
which also is used in urinary proteomics [43,44]. The most important strategy is referred to 
as multidimensional protein identification technology (MudPIT), where tryptic peptides are 
analyzed by multidimensional chromatography combined with mass spectrometry and 
search algorithms to identify proteins [45].  
In the current work a 2D-LC approach using Hydrophilic Interaction Liquid 
Chromatography (HILIC)-RP has been applied. HILIC can be described as normal phase 
chromatography, but with aqueous-organic mobile phase where water is the strongest 
solvent. The mechanisms of retention are still debated, but present theories suggest a 
partitioning of the analyte between the mobile phase and a water-enriched layer in the 
hydrophilic HILIC stationary phase. In addition to this, other mechanisms involving ion 
exchange, electrostatic interactions, dipole-dipole interactions and hydrogen bonding are 
likely to be contributors to retention. Several HILIC stationary phases have been developed 
and can roughly be grouped as neutral (diol, amide), charged (plain silica, aminopropyl) 
and zwitterionic (sufoalkylbetaine, silica- or polymerbound) phases. The zwitterionic 
(ZIC)-HILIC stationary phase was used in this thesis, where the active layer contains both 
strongly acidic sulphonic acid groups and strongly basic quaternary ammonium groups 
chemically bonded to silica as showed in Figure 3.  
 
 
Figure 3. Structure of the ZIC-HILIC stationary phase 
 
These groups strongly bind water by hydrogen bonding and make the bulk layer of water; 
which becomes a part of the stationary phase, the principal factor in controlling the 
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retention. Both ion exchange and electrostatics are weak compared to other HILIC phases 
and the main influence of retention is partitioning between the mobile phase and the 
adsorbed water layer for the ZIC-HILIC column. For an overview of different HILIC 
stationary phases and applications, see Hemström and Irgum [46] and also Jandera [47]. 
The use of a zwitterionic (ZIC)-HILIC column as the first dimension in multidimensional 
separation of proteins has shown promising results as an alternative to the more 
conventional methods [48]. Combination of HILIC and RP has shown to give a higher 
orthogonality and peak capacity compared with alternatives like SCX-RP and size 
exclusion chromatography (SEC)-RP [49]. Combination of high pH RP in the first 
dimension and low pH RP in the second dimension has also shown to give a relatively high 
orthogonality, but is limited by only affecting the retention time of peptides with basic or 
acidic groups [50]. 
 
Ionization and MS detection of peptides 
An important feature of using MS detection is the ability to identify proteins. A 
requirement for peptide detection in a mass spectrometer is that the molecule is ionized 
before entering the mass analyzer. Several combinations of ionization techniques and MS 
type have been applied in proteomics, but the most prominent techniques are matrix-
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) 
and ESI-MS/MS. MALDI-TOF-MS was not used for this work and will thus not be 
described further.  
The most common ESI configuration is on-line coupling of the liquid flow from the 
LC system directly into the ESI interface. In the interface, the liquid phase is pumped 
through a capillary where high voltage is applied resulting in formation of charged droplets 
pushed into a heating chamber. In the presence of nebulizer gas (nitrogen) the droplets go 
through several divisions while moving through the electrical field. This process repeats 
itself until the solvent is completely evaporated and only charged molecules are left, which 
then enter the mass analyzer. When using ESI, several charge states are possible (in 
contrast to MALDI). Nanospray is a low flow ESI, used at flow rates in the range of 
nanoliters per minute. The process is essentially the same as with regular ESI but because 
of the low flow rate, droplet formation occurs more readily requiring only applied voltage 
to generate spray. This means that no additional gas or heat is needed in the interface, 
improving both the stability of the spray and hence the signal. In addition, the ionization 
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efficiency is improved at such low flow rates due to less volume of mobile phase passing 
through the spray tip, producing smaller droplets.  
ESI can be coupled to several types of mass spectrometers often chosen based on 
application and information needed. Different types of mass analyzers were used in this 
work including ion trap, TOF, single quadrupole and linear ion trap-Orbitrap (LTQ-
Orbitrap). Geometry and principle of mass separation is different in each type of mass 
analyzer resulting in different properties such as mass resolution, mass range and ability to 
perform MSn. The latter is an important feature in order to gain structure information by 
fragmentation of the molecules. Several techniques are used to cause fragmentation, but 
collision induced dissociation (CID) is still the most prominent. CID causes backbone 
cleavage on the peptides following collision with Helium gas; yielding fragments which 
can reveal the amino acid sequence (see Figure 4). The most common fragments are y and 
b ions, where the y ions extend from the C-terminal while b ions extend from the N-
terminal. Analysis and interpretation of these ions (in addition to several other ions 
produced by fragmentation) are then used to elucidate the amino acid sequence of the 
peptide. 
 
 
Figure 4. The most common cleavage sites following CID fragmentation. (This file is 
licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license) 
 
The Orbitrap mass analyzer 
Several different types of mass analyzers were used in this work; most of them are 
established and have been used routinely for years. The Orbitrap (used in Paper IV and V), 
however, is a relatively new mass analyzer which already has made a large impact in the 
proteomics field; a short presentation of this mass analyzer will be given in the following 
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section. In 2000, Makarov described a new type of mass analyzer called the Orbitrap [51]. 
A model of this mass analyzer is shown in Figure 5. 
 
 
Figure 5. A model of the orbitrap mass analyzer (from reference [52] with permission) 
The Orbitrap is actually an ion trap that uses orbital trapping of moving ions in an 
electrostatic field, but without the use of magnet or dynamic (RF) electrical field like a 
more conventional ion trap [53]. This technique offers high resolving power (up to 
150000) and mass accuracy; mass deviations of sub-ppm has been reported in proteomics 
experiment [54]. Recently this was combined with a linear ion trap combining the mass 
spectrometric features of the ion trap with the high resolution and mass accuracy of the 
Orbitrap which resulted in the hybrid instrument named LTQ Orbitrap. This instrument 
consists of 3 main parts which are shown in Figure 6; the linear ion trap, a C-trap and the 
Orbitrap.  
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Figure 6. Schematic outline of the main components of the LTQ Orbitrap (from reference 
[52] with permission) 
 
The linear ion trap (the first part) is capable of detecting MS and MSn spectra at high speed 
and sensitivity but with low resolution and mass accuracy. Ions accumulated can then be 
transferred to the C-trap where they are accumulated and stored before sent into the 
Orbitrap in a pulse. The two mass analyzers can be used either separately or in 
combination depending on requirement of the analysis. In a typical proteomics experiment 
of an unknown sample both analyzers are normally used. The mass accuracy of the 
Orbitrap is used to obtain a very accurate mass of the precursor molecule, restraining the 
list of peptide candidates to a few sequences only. In parallel operation, the linear ion trap 
is used for fragmentation of wanted precursor molecules. This can theoretically also be 
done in the Orbitrap, but the linear ion trap is much faster and can deliver 3-5 spectra per 
second. The MS/MS spectra are usually detected in the linear ion trap but can also be sent 
to the Orbitrap for a more accurate mass detection. The high mass accuracy used for 
precursor detection is a clear advantage in peptide identification and largely decreases the 
problem with false positive peptide identifications which can be challenging when using 
low resolution mass spectrometers [55,56]. 
 
1.2.4 Quantification in urinary proteomics 
To improve the ability to accurately monitor changes in the protein expression both 
relative quantification and absolute quantification methodologies have been developed for 
use in proteomics [57-61]. Quantification in urine can be a challenge due to large day-to-
day variation in concentrations of proteins and peptides mostly related to varying fluid 
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intake [62]. Consequently, normalization of the proteome data is usually necessary. There 
are several approaches but none is perfect, although the use of normalization against total 
protein content is predominant in urinary proteomic studies [63]. 
Regarding relative quantification, most techniques are based on incorporating a 
stable isotope tag which results in a mass shift and enables comparison with an unlabeled 
sample [64]. One of the advantages of employing a relative quantification approach is the 
reduction of experimental variability. Hence, an early introduction of the labeling step in 
the proteomic workflow is beneficial to decrease the variability as much as possible.  
Several strategies for stable isotope labeling are available including isotope-coded 
affinity tags (ICAT) [58], isobaric tag for relative and absolute quantification (iTRAQ) 
[59], tandem mass tags (TMT) [60] and 18O-labeling [61,65]. In this work, 18O-labeling 
was the method of choice. Some of the advantages with this approach are that all 
proteolytically generated peptides are labeled (except C-terminal peptides) and at low costs 
compared with e.g. iTRAQ. One major disadvantage is that the procedure is relatively 
time-consuming and labor-intensive to achieve complete labeling. [66] 18O-labeling is 
performed enzymatically mostly using trypsin, but enzymes like Lys-C and Glu-C are also 
used [66,67]. Labeling is performed at peptide level, and an incorporation of two 18O 
atoms results in a mass shift of +4 Da for the labeled peptides.  
Incorporation of the 18O atoms by trypsin can be done in 2 different chemical 
reactions as shown in Figure 7 [68]. If H218O is present during tryptic digestion (amide 
bond cleavage), one 18O atom will be incorporated in each peptide. For the next 18O to be 
incorporated, a carboxyl oxygen exchange reaction must take place. This reaction is an 
equilibrium and hence required to occur multiple times to push the equilibrium towards 
two 18O atom incorporated and achieve complete labeling. When 18O-labeling is done 
separately from tryptic digestion, both 18O atoms are exchanged by the carboxyl oxygen 
exchange reaction.  
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Figure 7. Illustration of 18O-incorporation by two different mechanisms, amide bond 
cleavage and carboxyl oxygen exchange (From reference [68] with permission). 
 
Incorporation of both 18O atoms into the peptides is a very time consuming process 
[64,69], since it needs to be complete for reliable quantification. Several suggestions have 
been made to accelerate this process (ultrasound etc.) [70], but none has resulted in large 
improvement of the reaction time [66]. The carboxyl oxygen exchange reaction has fairly 
recently been reported to be pH dependent and far from ideal in the pH range of tryptic 
digestion, which has been the basis for many labeling protocols [69]. This has lead to 
recommendations of optimizing tryptic digestion and labeling conditions separately and 
rather use a decoupled procedure [66,69].  
 Another challenge with 18O-labeling is back exchange to 16O when labeled samples 
are mixed with unlabeled samples before LC-MS analysis, a reaction which is likely as 
long as trypsin is present [71]. To reduce this effect, immobilized trypsin on solid supports 
can be used for labeling since the trypsin can be separated from the solution stopping the 
labeling reaction. Sevinsky et al. also applied immobilized trypsin for protein digestion 
prior to labeling, in order to reduce the risk of back exchange further [72]. Despite these 
efforts to improve labeling, the reaction time remains a bottleneck in many 18O/16O-
labeling lasting up to 48 hours [72-74]. Accurate quantification can only be obtained with 
complete labeling. 
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1.2.5 Data acquisition 
Protein identification by mass spectrometry can be done either by Peptide Mass 
Fingerprinting (PMF) or by the use of tandem MS, both based on data from enzymatically 
digested proteins. Figure 8 shows a schematic workflow of the process when tandem-MS 
data are used for identification. The workflow is similar for PMF, but protein identification 
is carried out without MS/MS data and by only comparing detected masses with theoretical 
peptide masses obtained by in-silico digests of an entire protein database [75-79]. The 
general approach is similar in both cases. Experimental data are compared with calculated 
theoretically mass values obtained by applying appropriate enzyme information to entries 
in a database containing protein sequences (see later for different databases). 
Corresponding mass values are then scored in a way that allows for identification of the 
peptides and the proteins that best matches the peptide composition in the sample. 
 
Experimental data
(LC-MS/MS data)
Observed peptide ions
Acquired MS/MS spectra
Database 
(Swiss-Prot, IPI etc.)
Candidate peptides
Generate theoretically spectra
Score candidate peptides by search 
algorithm (Mascot, SEQUEST etc)
Highest score: peptide 
identification (and corresponding 
protein)
Validation of peptides
Validation of proteins
 
Figure 8. Schematic workflow for peptide/protein identification after LC-MS/MS 
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Several search engines with different scoring systems are used for this purpose and Mascot 
[80] and SEQUEST™ [81] are some of the most frequently applied. In the case of PMF, a 
fingerprint of molecular weights measured is used to match the theoretically peptides 
generated from proteins in the database of choice. A large number of identified peptides 
corresponding to a certain protein is a good fingerprint which yields a high score and hence 
a more confident identification. The use of PMF gives no sequence information for each 
peptide and is best suited for identification in relatively simple protein samples.  
In complex protein samples, more sequence information is required to achieve 
unambiguous identification of peptides and hence proteins. This is achieved by tandem MS 
[82], where specific fragment ions are used to determine the amino acid sequence of the 
peptides (see section 1.2.3. for peptide fragmentation). In the process shown in Figure 8, 
the observed peptide ions are compared with theoretically peptides possible from the 
database based on similarity of molecular weight. This search is done within a certain mass 
tolerance window which is relative small for high accuracy instruments (e.g. Orbitrap) and 
large for low accuracy instruments (e.g. ion trap). In practice this means that the list of 
candidate peptides will be much smaller and more defined for high accuracy data. Further, 
the experimental MS/MS data from each peptide mass observed is compared with 
theoretically spectra from the database. The search algorithms then gives each candidate 
peptide a score based on how many fragment ions that are matched with the theoretical 
spectra. This scoring system is relatively complex and involves different parameters 
depending on the algorithm used. The peptide with the highest score is assigned as a 
positive identification. All hits are usually validated to decide if the identification is false 
or true, typically including search against reverse databases and score thresholds. The 
resulting peptide list is then linked to the corresponding proteins for protein identification. 
A long list of peptide with high identification scores linking to a certain protein will 
typically generate a high protein score. In this thesis, the Mascot search engine was used in 
Paper I and III while SEQUEST was used in Paper IV and V.  
Proteome Discoverer, used in Paper IV and V, is a protein identification software 
platform for use with all mass spectrometers from Thermo Scientific (and some others). 
The platform works with both Mascot and SEQUEST™ search engines and supports 
several types of quantification methods (e.g. 18O labeling) where data can be obtained 
directly from .raw-files or other common spectrum data formats. There are several protein 
sequence databases, greatly varying in size and quality, available from different 
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consortiums to choose from for use in proteins searches. An example of this is the UniProt 
knowledgebase (UniProtKB) which consist of two sections. UniProtKB/Swiss-Prot 
contains only reviewed, manually annotated entries (525997, 8-Mar-11). The database is 
highly annotated including detailed information regarding protein structure, functions etc. 
and is updated at a regular basis. UniProtKB/TrEMBL is also based on high quality data, 
but is computer annotated and a supplement to Swiss-Prot containing all the translations 
from EMBL not yet integrated into Swiss-Prot (13897064 entries, 8-Mar-11). Other 
popular databases include NCBInr (largest and most frequently updated) and IPI, which 
contains single species databases from whose genome has been sequenced (includes 
combined protein entries from UniProtKB in addition to predicted protein sequences from 
Ensembl and RefSeq).   
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2 Aim of the study 
The current gold standard for diagnosis of suspected acute rejection episodes in kidney 
transplants is done by histological examination of renal core biopsies. This is primarily 
done to verify a suspicion of acute rejection based on a sudden increase in plasma 
creatinine that cannot be explained by other causes. The use of plasma creatinine as an AR 
biomarker is flawed by both its low specificity and the relatively late reaction time. This 
necessitates both the use of biopsies for verification and the use of powerful anti rejection 
therapy, which is associated with adverse events per se. If an earlier and more specific 
biomarker of AR episodes was available it may be that a minor adjustment of the 
immunosuppressive therapy would be enough to silence the early activated immune 
process. The clinical implications of this could be better long-term outcome for renal 
transplant recipients. Analysis of urine is particularly useful as biomarker matrix since it 
contains both proteins originating from plasma as well as locally in the kidney. Another 
important advantage is the non-invasive sampling as opposed to biopsies. 
 
To be able to analyze the urinary proteome, a method had to be developed and the specific 
aims were as follows: 
 Develop a sample preparation with high protein recovery and effective desalting. 
 Investigate different formats and technical solutions for tryptic digestion of 
proteins. 
 Develop a multidimensional chromatographic separation strategy. 
 Optimize and implement a relative quantification strategy based on stable isotope 
incorporation (18O/16O-labeling). 
 Optimize and streamline the complete procedure to achieve a high degree of 
downstream compatibility. 
 Downscale analysis to nanoscale separation (nanoLC-MS/MS) to increase 
sensitivity. 
 Investigate the variability of the method. 
 Investigate on-line alternatives. 
 Analyze urine samples from kidney transplants experiencing acute rejections to 
identify associated proteins. 
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3 Results and discussion 
The methodology in bottom-up proteomics is complex, time demanding, labor intensive 
and there are several possible pitfalls. In this thesis the focus has been on developing a 
urinary proteomics method to be able to find differentially expressed proteins associated 
with acute rejection episodes in kidney transplants. The first three papers have been 
focused around the sample preparation, tryptic digestion and the chromatographic 
separation. First of all, the workflow was optimized and streamlined to reduce the 
variability and maximize proteome information (Paper I) followed by investigation of 
different approaches for tryptic digestion (Paper II and III). In Paper IV, a quantification 
method was modified and implemented in the workflow before the complete method was 
utilized in the patient study (Paper V). The idea was to provide a solid analytical 
fundament in order to be confident that possible differential expressed proteins associated 
with acute rejection episodes were based on pathological changes and not poor 
repeatability of the method. In addition, much effort has been put on developing a more 
time efficient methodology than current standard protocols. 
 
3.1 Sample preparation and separation in urinary proteomics 
A bottom-up proteomics experiment is a complex multi-step procedure typically including 
sample preparation, depletion and multidimensional separation followed by MS-detection. 
Each step in the procedure is a possible source of variability and/or protein loss. In 
addition, the chemicals used in each step are not always compatible with the next step 
making extra sample handling necessary. Simplification and streamlining was one of the 
main principles laid to ground in the method development in order to decrease variability 
and increase repeatability and time efficiency. In addition, other parameters like protein 
recovery and separation selectivity of the chromatography was assessed to maximize the 
information obtained from the urinary proteome. Figure 9 shows the workflow and the 
solvents used in each step to demonstrate the downstream compatibility achieved as 
specified in the next chapters. 
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Urine
Centrifugation
9000 g, 5 min
Protein enrichment
Centrifugal filtration 5 kDa cut-off
(Vivascience)
HSA removal
Vivapure
Tryptic digestion
ZIC®-HILIC
RP-MS/MS
30 fractions
C18-tip clean-up
Solvent
…………...TrisHCl/NaCl pH 7.4
…….TrisHCl/NaCl pH 7.4
………….TrisHCl/NaCl (+ABC)
…………80 % MeCN
…………….80 % MeCN
…………….5 % MeCN  
Figure 9. Schematic outline of the main steps of the method workflow and solvents used in 
the respective steps. 
 
3.1.1 Sample collection and storage 
For the study in Paper V, urine was collected as part of an at that time ongoing study at 
Oslo University Hospital (n=20) [83]. All patients were followed prospectively during the 
early post transplant phase after transfer from the surgical department: Urinary samples 
were collected three times weekly the first two weeks, twice weekly the next four weeks 
followed by 1-2 samples per week until approximately 10 weeks after transplantation. 
Patient samples used in Paper I and IV was collected from anonymous kidney transplant 
patients in a stable phase post-transplant. Other urine samples used were from healthy 
individuals. All samples were collected as follows: Midstream urine were collected, left at 
4 °C for up to one hour, centrifuged at 800 × g for 10 minutes and stored at -70 °C. 
 
3.1.2 Sample preparation 
Choice of method 
For a successful urinary proteome analysis, isolation and purification of the proteins is 
necessary. In Paper I, several sample preparation approaches were tested. Criteria for 
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evaluation were high protein recovery, possibilities for enrichment and effective desalting 
of the sample. Table 1 (unpublished data) shows protein recoveries from commonly used 
protein enrichment methods like ethanol precipitation, centrifugal filtration and TCA 
precipitation followed by reconstitution in either 25 mM TrisHCl or 8 M Urea.  
 
Table 1. Protein recoveries from urine using various sample preparation methodsa 
Enrichment method Resuspension 
 25 mM TrisHCl 8 M Urea 
Ethanol 55 % 71 % 
Centrifugal filtration  
(5 kDa cut-off) 
58 % 92 % 
10 % TCA (1:5) <20 %b <20 %b 
a The recoveries were obtained adding 1200 µL TrisHCl or urea followed by 30 minutes on 
a rotary shaker at 600 rpm. 
bThe values were below the arbitrary limit of 20 %. 
 
Both ethanol precipitation and centrifugal filtration provided acceptable protein recoveries 
from urine in the range of 55 – 92 %. Precipitation using 10 % TCA had no effect in urine 
and only low protein recoveries (<20 %) were obtained. Since centrifugal filtration 
provided the best recovery in addition to low variability (RSD of 10 %, n = 4) it was 
chosen as the preferred sample preparation method in the further development of the 
strategy. The use of centrifugal filtration was also shown to be an effective desalting step, 
which is important for the further analysis of urine. 
 
Optimization 
In order to improve the recovery and thus covering a larger part of the proteome, different 
solutions with increasing volumes (600 µL – 2400 µL) were added to the remaining 
volume over the 5 kDa-filter of the device. Figure 10 shows that for all solvents tested the 
recovery increased with increasing volumes up to approximately 1800 µL. The highest 
recovery was obtained using 8 M urea, but this was considered to be unsuitable due to the 
downstream incompatibility with HSA depletion and the requirement of an extra step to 
remove excess urea. High recoveries were achieved with 10 mM TrisHCl/150 mM NaCl 
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(pH 7.4), and more important, this solution was downstream compatible with the HSA 
depletion step that made it a better choice than urea. 
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Figure 10. Protein recovery from centrifugal filters (5 kDa cut-off) using different volumes 
of water (×), 25 mM TrisHCl (▲), 25 mM TrisHCl + wash (∆), 8 M Urea (♦), 10 mM 
TrisHCl/150 mM NaCl (■), 10 mM TrisHCl/150 mM NaCl + wash (□) to redissolve the 
proteins after centrifugation 
 
HSA depletion  
In contrast to plasma, the concentration of the various proteins in urine seems to be more 
evenly distributed. Hence, the dynamic range is reduced and depletion of only HSA has 
been reported to be sufficient to be able to identify low abundant proteins in urine [28]. A 
combination of this and the risk of information loss after depletion (see chapter 1.2.1) lead 
to the choice of depleting only HSA. Gel electrophoresis of the samples (Figure 11, 
unpublished) showed efficient removal of HSA from urine using this kit. With only a 
minor pH adjustment, trypsin could be added directly to the depleted sample for protein 
digestion. 
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Figure 11. Gel electrophoresis of 2 urine samples depleted for HSA (red marking). Gel A 
was pure urine, gel B was spiked with HSA. Lane 1 in the gels shows crude urine prior to 
depletion. Lane 2-6 shows the flow-through fractions with depleted urine and lane 7 is a 
washing step. Lane 8 shows the fractions where trapped HSA from the samples is eluted. 
 
3.1.3 Chromatographic separation of the peptides 
A proteolytically digested protein sample usually yields highly complex peptide mixtures 
where the separation power offered by standard RP columns is far from sufficient to obtain 
quality data from the MS analysis. In order to improve this, the introduction of multiple 
chromatographic separations is often done to achieve a higher separation power and 
increased amount of information obtained. In Paper III, separation already at the protein 
level was investigated to decrease the sample complexity prior to tryptic digestion. The 
native proteins were separated by pH gradient strong anion exchange (SAX) 
chromatography. This was a component of an on-line multidimensional separation system 
that has partly been described previously [84]. In the earlier described system, the protein 
recoveries from the trap columns employed (C4 + C4) were relatively low. This was 
however greatly improved in this work by using a more acidic mobile phase (0.1 % formic 
acid) compared to the original mobile phase (0.1 % NH4OAc, pH 7.5). The protein 
recoveries were improved from 42 % to 76 % and 0.1 % formic acid was thus chosen for 
the further work.  
Advantages with this system was that valuable information from the native 
proteins, like e.g. pI, was obtained and the use of on-line coupling is potentially less prone 
to sample loss and contamination. It was however decided that the separation capability 
would be more advantageous using an approach with multidimensional peptide separation 
and protein separation on top of this would be too comprehensive and labor-intensive for 
each sample. Protein separation was thus not included in the final method used for the 
A. Urine B. Urine spiked with HSA 
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patient study (Paper V). As described in section 1.2.3, the combination ZIC-HILIC-RP has 
shown promising results as separation system in proteomic analysis due to the high 
orthogonality of the two column types. The combination was investigated in Paper I and, 
based on the performance, made the preferred separation system for the further work 
(Paper IV and V). 
 
First-dimension separation: ZIC-HILIC 
In the development phase both 80 % MeCN and 95 % MeCN were investigated as starting 
conditions for the gradient elution and also sample solvent for the respective setups. 
Chromatograms separating a cyt c digest in both gradients are displayed in Figure 12, 
which shows a significant difference not only in peak height of the peptides, but also in 
total number of peaks detectable.  
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Figure 12. The upper chromatogram shows gradient elution separation of a tryptic digest 
of cyt c on a HILIC column starting at 80 % MeCN. The lower chromatogram shows 
separation with 95 % MeCN as gradient starting conditions. Both samples were dissolved 
in its respective starting mobile phase and equal concentrations of cyt c were used. 
 
This may be due to decreased solubility of the peptides in the 95 % MeCN mobile phase, 
which particularly affects the hydrophilic peptides. As a consequence only the most 
hydrophobic peptides may be solubilized resulting in lower peak heights and fewer peaks. 
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Hence, it was decided that 80 % MeCN was used as gradient starting mobile phase and as 
sample solvent. 
 
Second-dimension separation: Reversed Phase 
Reversed phase (RP) chromatography was used as the separation technique in the second 
dimension when multidimensional separation was applied. This was due to the ideal 
combination when coupled to HILIC as pointed out in the previous section. Additionally, 
RP separation was carried out as only dimension when used as analytical tool in the 
development work. Initially, microscale columns (1 mm ID) where used for separation but 
downscaling was necessary particularly to increase the sensitivity for the analysis of the 
patient samples. In Paper I, capillary columns (0.32 mm ID) were used in combination 
with short trap columns of larger diameter (1 mm ID), enabling large injection volumes (50 
µL), to increase the sensitivity. As described later, in section 3.2.5, this increased the 
number of identified peptides/proteins substantially.  
Further downscaling was done in Paper V, utilizing nano separation (75 µm ID 
columns) in combination with nanospray ionization and trap columns (0.32 mm ID) that 
enabled the same injection volumes as in Paper IV. As expected from chromatography 
theory, the sensitivity of this approach was superior to the configurations using larger 
columns and a large number of peptides and proteins were identified with a high degree of 
confidence. This is effectively demonstrated in Figure 13 where corresponding fractions 
from two different experiments distinguished by the use of hence nano- and microscale 
columns are presented. The scales on both y-axes have been normalized against total 
protein concentration in the respective samples and are hence directly comparable. In the 
chromatogram where a micro column is used, few peaks are possible to separate from the 
baseline noise of the chromatogram. The other chromatogram, utilizing nano separation, is 
highly complex showing a large number of peaks. While the use of low flow 
chromatography offers superior sensitivity, there are several pitfalls and challenges by 
using such a system compared with normal flow. One of the challenges is that even small 
compartments of dead volume can have a large impact on the chromatography in a nano 
system while it would not even have affected a normal flow system. This makes the use of 
correct tubing and couplings of outmost importance to minimize these effects. Furthermore 
are mounting of columns and changing of other parts of the flow-line critical operations 
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where small details like for example an inadequate tightened coupling can lead to large 
changes of the chromatography. Identification of such problems could also be challenging 
since leakages are hard to discover due to the low flow in the system. 
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Figure 13. Chromatograms of corresponding fractions analyzed in the second dimension 
from two similar experiments distinguished by the use of nano and micro columns 
respectively. The samples contained comparable amounts of total protein. 
 
Finally, the combination of the HILIC and RP was tested to gain information on the peak 
distribution and orthogonality with the chosen conditions. A tryptic digested urine sample 
from a renal transplant recipient was used to demonstrate the orthogonality of the system. 
The fraction number from the ZIC-HILIC separation was plotted against the retention time 
of the peaks in the 2nd dimension (RP) shown in Figure 14.  
27 
 
 
R² = 0.004
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25 30
t R
RP
 (m
in
)
Fraction no. HILIC
 
Figure 14. Plot of retention time (tR) of peaks in the 2nd dimension (RP) vs. fraction 
number from the 1st dimension (HILIC). The sample used was from a kidney transplanted 
patient 
 
The plot shows a rather even distribution of peaks throughout all fractions and gives a 
good overview of the peak distribution and the difference in selectivity between the two 
dimensions. Another observation is that the distribution on the second axis (retention time 
2nd dimension) is comparable in all fractions suggesting that the system is quite orthogonal, 
something which is also supported by the regression factor (R2 = 0.004) indicating little or 
no linear correlation between the two dimensions. 
 
3.1.4 Variability of the method: step by step evaluation of the workflow 
The many steps that make up a complete proteomic experiment are all possible sources of 
variability. Various precautions can be taken to reduce this to a minimum, where the 
ultimate aim is no methodological variability at all. This is however unrealistic and 
identification of the method related contribution to variability is hence useful for 
quantification purposes. In order to evaluate the variability of the current method, 6 
replicates of a pooled urine sample from 3 renal transplant recipients were analyzed. These 
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were true replicates prepared separately through the whole workflow. Relevant parameters 
from each step were evaluated, summarized in Table 2.  
 
Table 2. Overview of key variables and variability in different steps of the workflow 
Workflow step Variable Value RSD  
(%)a 
Sample preparation Protein recovery 5.6 mg/mL 9.2 
HSA depletion Protein recovery 1.7 mg/mL 6.7 
1st dimension LC (HILIC) Retention time 5.8 – 27.4 min 0.35b 
2nd dimension (RP-MS/MS) Peak intensity 4e5 – 7e6 units 28c 
a n=6 for all steps, pooled urine from kidney transplanted patients. 
b average of 8 peaks in the retention window specified 
c average of 30 peaks from 3 fractions 
 
Protein recovery was the measured variable after both sample preparation and HSA 
depletion. This functions as a rough parameter of the total proteome isolated and RSD 
values of 9.2 % and 6.7 % were calculated for the respective steps. In the first dimension of 
the two-dimensional separation, the variability of the retention time ranged from 0.15 % - 
0.82 %. Large variability of the retention time in the first separation dimension is 
unfavorable since it will have a large impact on the composition of the fractions analyzed 
in the second dimension. The last variable was peak intensity in the second dimension. 
Intraday RSD varied between 11 % and 30 % depending on the fraction. Besides variations 
in the last step itself, the peak intensity also reflects total variations through every step in 
the method. Both variations in protein recovery and retention times in the first dimension 
affect the signal variability in the last step in addition to sources directly related to that step 
(e.g. electrospray ionization). 
 
3.2 Tryptic digestion & protein identification 
3.2.1 Optimization of digestion conditions using immobilized trypsin beads 
Tryptic digestion of proteins has traditionally been carried out in-solution [85,86], which 
also was the case in Paper I. The procedure is well established but suffers from long 
reaction time and is typically done overnight. As a strategy to reduce the total time frame 
of the workflow, enzymatic digestion using immobilized trypsin was tested as a 
replacement for in-solution digestion (Paper II). The digestion time is described to be 
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strongly reduced because of the high effective protease concentration on the solid support 
compared to in-solution digestion. Different digestion reactors were investigated (see 
Figure 15) using BSA as a model substrate for the optimization of the digestion.  
 
A B C D
 
Figure 15. Different digestion reactors (A-D) which were investigated 
 
Reactor D showed the best digestion efficiency and offered the possibility for effective 
wash-out of proteins/peptides from the beads promoting possible re-use. This format was 
thus chosen for the further optimization experiments. The optimal condition for BSA 
digestion was found to be a reaction time of 89 minutes at 37 °C using 800 rpm agitation. 
For the development of quantification method (Paper IV) and hence the optimized method 
used in chapter 3.4 (Paper V), reactor A was used instead of reactor D. Reactor A yielded 
almost equal digestion efficiency and the risk of sample loss was considered lower than in 
reactor D, an essential aspect in the method development in Paper IV. Additionally, the 
beads were not intended for re-use which was an important benefit of reactor D. 
 
3.2.2 In-solution digestion vs. digestion on immobilized trypsin beads 
Even though proof of concept was demonstrated in the early results, showing extensive 
protein digestion within minutes, benchmarking against the established method was 
necessary. The optimized digestion procedure using immobilized trypsin beads (BSA in 
reactor D) was compared with digestion in-solution by parameters like visual comparison 
of the resulting chromatograms, peak intensity of digestion products, sequence coverage, 
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masses matched and amount of uncleaved peptides. The qualitative information obtained 
from the two methods was comparable looking at signal intensity and sequence coverage, 
but differences in digestion kinetics are likely based on the results. However, the slightly 
lower number of peptides with missed cleavages identified using immobilized trypsin 
indicates a better completeness of the digest. Including the substantial reduction of reaction 
time from overnight to 1.5 hours, the benefits of using immobilized trypsin are 
conspicuous. 
 
3.2.3 Digestion efficiency in human urine 
Following the promising results in buffered solutions, testing of the procedure in a more 
complex matrix was necessary to assess the usefulness in a biological experiment. This 
was done by performing BSA digestion in a complex urine sample using immobilized 
trypsin beads and comparing with an equivalent experiment in a buffered sample. Signal 
intensity of 12 peptide products were monitored and the urine sample was depleted for 
HSA to ensure that a minimum of HSA peptide products would interfere with the peptide 
products from BSA. The results are summarized in Table 3, where peak intensities 
obtained in aqueous buffer and urine are compared. Similar intensities were found for 
many peptides, however, both higher and lower intensities of several peptides were 
observed after digestion in urine compared to in buffered solution. This could be due to 
different reaction kinetics in urine, possibly related to foreign components. Another factor 
contributing to the differences detected, could be presence of co-eluting compounds 
suppressing ionization of certain peptides in the MS-analysis. Noteworthy, Table 3 also 
shows that repeatability is good for the tryptic digestion in urine. RSD values below 10 % 
for all peptides (except one), are well within the limits of acceptance for determination of 
compounds like drugs in biological matrices. 
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Table 3. Identified peptides of BSA in urine and buffer 
   BSA digest in urine (n=3) BSA digest in buffer (n=3) 
m/z 
peptide 
Specificityc 
Present in BSA/HSA? 
Missed 
Cleavages signal intensity (x103) RSD (%) signal intensity (x103) RSD (%) 
       
395.3 
LVTDLTK 
BSA and HSA 
0 122.7 4.7 202 0.9 
417.2 
FKDLGEEHFK 
Only BSA 
1 8.3 6.9 76 3.5 
461.7 
AEFVEVTK 
Only BSA 
0 71.7 3.5 191 6.0 
435.9 
HLVDEPQNLIK 
Only BSA 
0 39 5.1 24.3 11.9 
547.3 
KVPQVSTPTLVEVSR 
BSA and HSA 
1 51 11.8 89.7 8.1 
582.3 
LVNELTEFAK 
Only BSA 
0 104 6.7 80.7 25.1 
507.8 
QTALVELLK 
Only BSA 
0 118.7 2.9 130 15.0 
818.4 
ATEEQLK 
Only BSA 
0 5 b <5 a 
634 
LGEYGFQNALIVRYTR 
Only BSA 
1 <5 a 5.5 b 
815.7 
DDSPDLPKLKPDPNTLCDEFK 
Only BSA 
2 9 b 5 b 
589.8 
HLVDEPQNLIKQNCDQFEK 
Only BSA 
1 11.3 5.1 25.3 13.9 
 a signals were observed but below the arbitrary limit of 5x103.  
b one of the signals observed was below the arbitrary limit of 5x103. 
c From BLAST analysis: http://www.ncbi.nlm.nih.gov/blast/Blast.cgi 
 
3.2.4 On-column reduction, alkylation and tryptic digestion 
In order to look for other alternatives regarding tryptic digestion, an approach using 
integrating tryptic digestion on-line with multidimensional separation was investigated 
(Paper III). One of the benefits with on-line systems is the possibility for automation that 
in turn could increase sample throughput. The system consisted of pH gradient SAX 
chromatography of native proteins in the first dimension which then were fractionated and 
stored on trap columns (C4-C4) for subsequent on-column reduction and alkylation. The 
alkylated proteins were then transferred to an analytical C4 column for separation followed 
by on-column tryptic digestion coupled to ESI-MS detection (see Figure 16 for flowchart). 
Four proteins (lysozyme, β-lactoglobulin A, myoglobin and HSA) containing varying 
amounts of cystein groups (site of alkylation) were used to evaluate the performance of the 
reduction/alkylation step. Overall, the results showed a very efficient alkylation of both 
proteins with few cystein groups (e.g. β-lactoglobulin A) but also of the cystein-rich 
protein HSA.  
To investigate the digestion efficiency of the TPCK-trypsin column in the system, a 
mixture of 5 proteins was analyzed. The mixture was digested in two modes; continuous-
flow and stop-flow (flow stopped for 30 minutes). The results were satisfying for the 
majority of the proteins yielding sequence coverage in the range of 65 – 75 % in the 
continuous mode and 74 – 90 % in stop-flow mode. The procedure was not optimal for β-
lactoglobulin A, where several peaks from the intact protein were observed. Digestion of 
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the largest protein in the mixture (HSA) was neither optimal, yielding few tryptic peptides 
even in stop-flow mode. In general, stop-flow mode produced a larger number of peptides 
and better sequence coverage but increased the total analysis time of one sample with 4.5 
hours (9 fractions). Despite the benefits of automation, this approach was not chosen for 
the final setup (Paper V). This was mainly due to varying digestion quality (need for 
further optimization), complex setup and difficulties including 18O-labeling (Paper IV) in 
the procedure. 
 
 
Figure 16. Scheme of the on-line coupled instrumentation system 
 
3.2.5 Protein identification by different analytical platforms 
In the method development, different LC-MS/(MS) equipment were utilized. The columns 
used ranged in size from micro (1 mm ID, Paper II and IV) to capillary (0.32 mm ID, 
Paper I and III) and nano (75 µm ID, Paper V). In addition, trap columns were used in the 
capillary and nano setup to increase the injection volume and hence sensitivity. Both low 
resolution MS equipment like ion traps (Paper I and II), and high-resolution MS 
instruments like TOF (Paper III) and LTQ-Orbitrap (Paper IV and V) was used for 
detection. The ion traps and LTQ-Orbitrap also provides MS/MS capabilities. Choice of 
equipment was partly based on availability but also according to certain specifications 
depending on use. In Table 4 the different platforms are compared with respect to number 
of peptides and proteins identified. The combination of miniaturized chromatography 
including trap columns and MS/MS identification resulted in a significant higher amount 
of identified proteins compared with the other platforms. Not surprisingly, the highest 
number of identified proteins was achieved using nanoscale chromatography coupled to 
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the LTQ-Orbitrap where up to 1022 proteins were identified in one single sample (the 
average was 670 proteins).  
 
Table 4. Different platforms used for peptide/protein identification 
Paper LC MS ID Peptides Proteins 
I Cap. Ion trap (Bruker Esquire 3000plus) MS/MS 1668 438 
III Cap. Time of Flight (LCT Micromass) PMF 46 4 
IV Micro LTQ-Orbitrap (Thermo) MS/MS 88 56 
V Nano LTQ-Orbitrap (Thermo) MS/MS 2710 670 
 
In addition to the many proteins identified, the amount of false positive identified 
peptides/proteins is probably lower than compared with results obtained using ion trap 
MS/MS. This is related to the high mass accuracy of the Orbitrap, which reduces the 
number of possible peptide hits from a certain m/z-value considerably. In Paper V, the 
identified proteins were also validated by searching against the reversed database in order 
to eliminate false positive identifications. This was not done in Paper I. Even though a 
complex peak profile was seen in the chromatographic separation in Paper III, few 
proteins were identified in the fractions analyzed. This is probably strongly correlated to 
the use of PMF, which has considerable limitations in complex protein samples. If MS/MS 
had been used for identification, the list of identified proteins would probably be larger. 
Another striking observation is the large difference in identified proteins when going from 
microscale (Paper IV) to nanoscale chromatography (Paper V), even though the sensitive 
LTQ-Orbitrap is used as MS-detection in both cases. This is closely related to the 
increased sensitivity as pointed out in section 3.1.3.2 and showed in Figure 13. 
 
3.3 Accelerated quantification in urinary proteomics utilizing 18O-
labeling 
As described in section 1.2.4; 18O-labeling was chosen as the preferred quantification 
strategy for the current work. There was however a potential for, and need to optimize the 
weak points of the existing procedures. Focus of the experiments was not to study each 
reaction in detail but a more practical approach, optimizing a method best fit for the 
application. The first area of focus was to improve the rate of the labeling reaction in order 
to achieve complete labeling and within a reasonable time frame. Secondly, one of the 
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biggest challenges of 18O-labeling has been back exchange of 16O after labeling making the 
quantification result less reliable. Immobilized trypsin beads were used in effort to 
decrease this effect. Moreover, other precautions as for example addition of 8 M urea to 
stop the trypsin effect after labeling was implemented to avoid back exchange. Finally, the 
knowledge on shorter tryptic digestion using immobilized trypsin beads (Paper II) was 
used to establish a common platform for both digestion and labeling. The incentive was to 
get a more time- and work-efficient procedure. In every experiment, equal amounts of 
digested protein after 18O- and 16O-labeling were mixed. The 18O/16O-ratio should then, 
under ideal conditions, be 1:1. 
 
3.3.1 pH dependency and reaction time optimization 
As previously mentioned, the rate of the carboxyl oxygen exchange reaction can be greatly 
accelerated by optimizing pH for the labeling step independently from the conditions used 
for tryptic digestion [69]. The reported optimum labeling conditions were at pH 6 when 
trypsin was used. To investigate this further, an experiment assessing both pH and reaction 
time was carried out to identify the conditions where complete labeling could be achieved 
in the shortest possible time. The anticipated optimum of pH 6 was used as the starting 
point and different length of reaction time at this pH was investigated as presented in 
Figure 17. 
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Figure 17. Average 18O/16O-ratios (±SD) of 12 BSA / cyt c peptides at different time points 
(n = 3). Labeling was done at pH 6 
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The results showed that extensive labeling was accomplished already after 15 minutes, but 
complete labeling was not achieved before 2 hours reaction time. Increasing the reaction 
length further produced the same 18O/16O-ratios and no reduction in variability was 
observed. In order to confirm the pH optimum reported by Hajkova et al. [69], the labeling 
reaction was carried out at different pH levels ranging from pH 5 to pH 9. The reaction 
time was set to 2 hours, which was shown to be sufficient for complete labeling at pH 6. 
The results presented in Figure 18 confirmed pH 6 as the optimum pH in the chosen pH 
range and also that the efficiency was rapidly declining moving up or down the pH scale.  
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Figure 18. Average 18O/16O-ratios (±SD) of 12 BSA / cyt c peptides using labeling buffer 
of pH 5, 6, 7, 8 or 9 (n = 3). Reaction time was 2 hours for all samples 
 
In both the pH and reaction time experiments, differences between lysine- and arginine-
terminated peptides were observed. At pH 6 there was a clear tendency of faster labeling of 
peptides with arginine at the C-terminal, 3 out of 4 peptides monitored were actually 
completely labeled already after 15 minutes. This corresponds well with previously 
published work reporting problems with incorporating two oxygen atoms efficiently into 
lysine terminated peptides. [87]. The ratio of the lysine terminated peptides increased at a 
much slower rate than arginine terminated peptides. In addition the variability in efficiency 
between the lysine terminated peptides was large, obviously dependent on peptide 
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properties. The pH experiment also showed a tendency of different reaction kinetics 
between arginine and lysine terminated peptides. All of the peptides were completely 
labeled after 2 hours at pH 6. But while the lysine terminated peptides were poorly labeled 
at pH 7 (2 hours), the majority of the arginine terminated peptides were completely labeled 
at this pH as well. Arginine and lysine are quite similar amino acids but the pKa-value of 
both the N-terminal and particularly the side chain is lower for lysine than for arginine. 
This could be a plausible explanation for the different labeling kinetics, suggesting that 
degree of protonation could play a role in the labeling process. Nevertheless, the optimum 
labeling conditions for all the peptides were at pH 6 which was used in the further work 
combined with a reaction time of 2 hours. 
 
3.3.2 Integration of digestion and labeling using immobilized trypsin beads 
The increased digestion efficiency observed after implementation of immobilized trypsin 
beads (section 3.2.1) combined with the fact that both the digestion and labeling steps were 
carried out using trypsin beads, lead to the idea of a closer integration of the two steps. The 
idea of tryptic digestion using immobilized trypsin prior to the labeling step has been 
described earlier, but not integrated in one sample reactor and done without optimized 
conditions in each step [72]. A more time efficient and less labor intensive procedure was 
the main motivation behind the idea of integration, encouraged by the experiments in 
section 3.2.1 and 3.3.1 proving the potential in optimizing the established procedures. 
Challenges like different reaction pH for the two reactions and introduction of H218O in 
appropriate amount to keep the cost at a reasonable level had to be solved. Figure 19 shows 
the complete optimized approach integrating tryptic digestion and 18O-labeling in one 
procedure.  
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Figure 19. Overview of the integrated digestion and labeling procedure on immobilized 
trypsin beads. The sample is first digested in ammonium hydrogen carbonate buffer (in 
H216O) followed by evaporation. The sample is then reconstituted in H218O containing 
buffer (pH 6) and extra trypsin beads (separate vial). Labeling is then carried out in the 
same vial as the digestion, and is stopped by removing trypsin beads and adding 8 M urea. 
Corresponding 16O- and 18O-labeled samples are mixed in a 1:1 ratio before LC-MS/MS 
analysis 
 
The use of the volatile buffer ammonium hydrogen carbonate (pH 8) in the digestion step 
enabled buffer exchange by a simple evaporation step, followed by reconstitution in the 
labeling buffer (pH 6). In addition, the whole procedure was carried out without any 
transfer steps, greatly reducing possible sources of sample loss. The initial results yielded 
acceptable average ratios (Figure 20, result b), but the variation observed was noteworthy 
larger than compared with overnight in-solution digestion combined with labeling on 
immobilized trypsin (result a). The solution was to add an aliquot of fresh trypsin beads to 
the reaction vial between the digestion and labeling step, which reduced the standard 
deviation to a level below what was observed in the original setup.  
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Figure 20. Average 18O/16O-ratios (±SD) for 12 BSA/cyt c peptides (n = 3). (a) Tryptic 
digestion in-solution/labeling on immobilized trypsin. (b) Both tryptic digestion and 
labeling on immobilized trypsin beads. (c) Both tryptic digestion and labeling on 
immobilized trypsin beads, extra beads added between the steps 
 
Introduction of immobilized trypsin beads in the labeling and digestion steps introduces a 
risk of unspecific binding of peptides to the beads that could lead to lower recoveries. On 
the other hand the integrated approach has no sample transfer steps, an improvement that 
could prevent peptide loss compared to the original procedure. To evaluate how the 
replacement of in-solution digestion with the integrated approach using immobilized 
trypsin digestion affected the final peptide concentrations, peak intensities of selected 
peptide products from BSA and cyt c were compared for the different setups. The results 
are displayed in Table 5, showing the relative intensity change of the peptides going from 
in-solution to immobilized trypsin. All of the peptides evaluated, except LVTDLTK and 
LVNELTEFAK, increased in signal intensity when using immobilized trypsin beads. The 
peak intensity of some of the peptides increased dramatically, especially EDLIAYLK and 
EETLMEYLENPK, which increased by 1704 % and 3794 % respectively. In conclusion, 
most of the peptides increased in peak intensity with the integrated approach, most likely 
because of the reduced need for sample transfer. All these results indicate that digestion 
and labeling can be performed in a satisfying manner using immobilized trypsin in both 
steps. An important aspect is the time-efficiency of this procedure, enabling reduction of 
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total reaction time of tryptic digestion and labeling from approximately 32 hours to a total 
of 3.5 hours. 
 
Table 5. Intensity change of tryptic peptides from BSA and cyt c after replacing tryptic 
digestion in-solution with digestion using immobilized trypsin beads 
Protein Peptide sequence m/z Intensity change 
BSA LVTDLTK 395.24+2 -27.7 % 
 AEFVEVTK 461.75+2 23.5 % 
 YLYEIAR 464.25+2 11.3 % 
 HLVDEPQNLIK 653.36+2 12.7 % 
 KVPQVSTPTLVEVSR 547.32+3 240.2 % 
 LVNELTEFAK 582.32+2 -3.8 % 
 LGEYGFQNALIVR 740.40+2 71.2 % 
 QTALVELLK 507.81+2 366.9 % 
    
Cytochrome c MIFAGIK 390.23+2 269.9 % 
 TGPNLHGLFGR 390.21+3 231.8 % 
 EDLIAYLK 482.77+2 1704.5 % 
 EETLMEYLENPK 748.35+2 3794.3 % 
 
 
3.3.3 Efficiency of the optimized procedure in urine samples 
The developed integrated method was also tested in true urine samples to see the 
applicability in a complex and more protein rich matrix. Evaluation of the performance 
was done in urine samples spiked with a mixture of BSA and cyt c prior to tryptic 
digestion using the optimized procedure from section 3.3.2. The average 18O/16O-ratios of 
the 5 replicates ranged from 0.73 to 1.05 with an average of 0.88. RSD values below 16 % 
were observed in 4 out 5 samples, which is comparable to work published using iTRAQ 
where standard deviations less than 23 % were reported [59]. Another group investigating 
the variation of iTRAQ labeling has previously reported a coefficient of variation (CV) = 
24 % [88], while Gan and coworkers classified the variation into different sources: 
technical (±11%), experimental (±23%) and biological (±25%) variation [89]. The 
variability of the integrated 18O/16O labeling approach was hence comparable or even 
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better than in the earlier reported works. Average 18O/16O ratios obtained in urine 
suggested complete labeling and low degree of back exchange. In order to confirm this, a 
sample of 18O-labeled BSA in urine was analyzed before mixing with unlabeled peptides. 
Prospective peaks showing 16O-labeled (not labeled) peptides could then only be caused by 
incomplete labeling or back exchange. The mass spectra of six of the 18O-labeled BSA 
peptides are shown in Figure 21.  
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Figure 21. Orbitrap mass spectra of six 18O-labeled BSA peptides before mixing with 
unlabeled peptides. (a) LVTDLTK, (b) AEFVEVTK, (c) YLYEIAR, (d) HLVDEPQNLIK, (e) 
KVPQVSTPTLVEVSR, (f) LGEYGFQNALIVR. Spectra were obtained from urine spiked 
with BSA, digested and labeled by immobilized trypsin 
 
Traces of 16O-peptides and singly 18O-labeled peptides are visible in the mass spectra, but 
in low amounts relative to doubly 18O-labeled (<3%). This is explained by the use of 97 % 
pure H218O (thus having 3 % H216O present). In other words, these results also support that 
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the labeling is complete and a very low degree of back exchange takes place. Application 
of the method on a realistic patient sample (kidney transplant) was the final test to evaluate 
the labeling efficiency in a broad range of peptides originating from urinary proteins. 
Another aspect was to see how the integrated digestion/labeling approach would function 
as part of a comprehensive proteomic experiment and how the results and variability would 
be affected. Figure 22 shows the ratio distribution of identified peptides in 2 replicate 
samples.  
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Figure 22. Ratio distribution of all 18O/16O-labeled peptides identified (x-axis) in urine 
from a kidney transplanted patient (n = 2). Both tryptic digestion and 18O/16O-labeling 
were done using immobilized trypsin 
 
Average peptide ratios of 0.83±0.13 and 0.91±0.27 (no statistical significant difference) 
suggest that a high degree of labeling is achieved and the standard deviation also shows a 
relatively low degree of variation between the peptides. The respective median ratios were 
0.84 and 0.94, indicating symmetric distribution. Based on these results, the integrated 
digestion/labeling approach was chosen for the further studies enabling rapid digestion and 
labeling without compromising on the quality. 
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3.4 Differential expressed proteins following acute rejection in renal 
transplant recipients 
As pointed out in the introduction of this thesis, a better tool to diagnose acute rejection 
episodes is desired. To improve current methods, a specific and more sensitive biomarker 
that could be obtained non-invasively (urine) and detect initiating rejection episodes at an 
earlier time would have been of great value. Several attempts have been made to identify 
possible urinary markers predicting AR [90-101], but so far none of them are routinely 
used in a clinical setting [102,103]. Most of the studies done are hypothesis based and 
performed by analysis of a few specific targets. However, Sigdel et al. recently applied 
shotgun proteomics to identify possible AR markers in pediatric kidney transplants [100]. 
This is a less biased approach based on screening of all proteins that are possible to 
identify in a sample. A similar approach was chosen in this thesis using the LTQ-Orbitrap 
that benefits from a high mass resolution to identify proteins with a high degree of 
confidence. In the work of Sigdel et al., a label free quantification approach based on 
spectral counting was used. This is a semi-quantitative approach, which especially for low 
intensity peaks is less precise than quantification by stable isotopic labeling (e.g. 18O/16O-
labeling) used in this thesis. The analyses were based on individual samples, not of pooled 
samples from many patients, avoiding bias from extreme individual changes in the 
proteome. In addition, analysis of individual samples also provides information on inter-
individual variation. Detection of up-regulation of certain protein biomarkers in urine 
could provide a non-invasive and effective way to diagnose acute rejection episodes 
following renal transplantation. 
 
3.4.1 Choice of patients and samples 
In Paper V, urine were collected from renal transplant recipients as part of an ongoing 
clinical study (n=20) [83]. The patients were followed prospectively from the time they 
were transferred from the surgical department (typically five days after operation) and 
urine samples were collected until approximately 10 weeks after transplantation. The urine 
samples were collected several days each week and clinical data collected for the whole 
period. All suspected acute rejections were verified with a biopsy and classified according 
to Banff 97 [9]. In order to find proteins associated with AR, urine samples from the day a 
biopsy was taken to investigate if there was a true acute rejection episode were compared 
with the first urine sample available after transplantation (baseline) by the proteomic 
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method described and developed in this thesis. An overview of the samples compared is 
displayed in Figure 23. This approach, as compared to the more commonly used pooled 
sample strategy, also gives a more informative picture since inter-individual variability can 
be assessed. The AR sample was also compared with a sample obtained in a clinically 
stable phase 7-11 days prior to acute rejection (before increased plasma creatinine) in order 
to get information on protein levels close up to verified AR. Samples from 6 AR patients 
were analyzed and compared with a control group consisting of 6 subjects not experiencing 
AR in the same clinical trial. In the control group, baseline samples were compared with 
samples from a clinically stable phase post-transplant from the same patient matched in 
time against the AR-group. 
 
Acute rejection 7-11 days before ARBaseline
16O 16O18O18O
Up/down-regulated 
proteins
Up/down-regulated 
proteins  
Figure 23. Scheme of the samples analyzed and compared from each patient 
 
3.4.2 Up-regulated proteins 
It was decided to focus on up-regulated proteins since these probably are the most relevant 
and interesting proteins in a clinical setting. Furthermore would an opposite labeling 
probably be more suitable to quantify down-regulated proteins. In particular for the highly 
down-regulated proteins where the isotope pattern from the unlabeled peptide peak would 
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interfere with the low signals from the labeled peptide giving uncertain quantification 
results. Hence would labeling of the baseline sample with the heavy tag (18O) be more 
appropriate to avoid this effect. In order to identify proteins associated with AR, changes in 
protein levels from baseline to AR was investigated. Up-regulation of a certain protein was 
defined as a ≥1 fold log 2 change of the 18O/16O-ratios from baseline to AR. In other 
words; a doubling of the protein levels from baseline to AR would define a protein as up-
regulated in a single patient. This high threshold minimizes the impact of methodological 
variability, which was substantially lower (calculated in section 3.1.4). The list of the most 
up-regulated proteins in this study was selected based on several criteria where the first 
was an up-regulation (fold change of ≥1, log 2) in at least three patients in the rejection 
group. Further, proteins with higher average ratio in the control group and proteins more 
frequently up-regulated in the control group were excluded to remove proteins that 
increased in all patients after transplantation, thus probably unrelated to AR.  
This resulted in a list of 11 proteins, which could be grouped by biological function 
in two main groups; proteins involved in regulation of growth and proteins involved in 
immune response. One protein, MEP1A, did not fit any of these groups and is presented 
individually. The list of grouped proteins and ratios in each patient of both the rejection 
and control group are showed in Table 6. Only the Mannan-binding lectin serin protease 2 
(MASP2) was up regulated in all rejection patients. Grouping the proteins by biological 
functions substantiated however a potentially relevant regulation within these systems in 
the rejection group as compared with the control group. This was done by combining all 
proteins within each group of proteins into one score based on the log 2 changes from 
baseline. Figure 24 shows the change in protein levels for specified protein groups in the 
six patients experiencing AR. 
A very interesting and important finding is the up-regulation detected several days 
prior to the acute rejection was clinically suspected as illustrated in Figure 24. Any 
rejection is an on-going process and it is well known that it takes time before creatinine 
increases enough (>20%) so that a rejection is suspected. If the altered urine proteome 
turns out to be an earlier responding and more specific biomarker of acute rejection it 
could have dramatic implications on long term outcome of renal transplant recipients. It is 
possible that a minor adjustment of the immunosuppressive therapy would be enough to 
“silence” the early activated immune process and actually avoid full activation of the 
immune system. Sequential urine proteomic analysis could possibly serve as an 
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“immunometer” also during tapering of the initial high immunosuppressive load after 
engraftment. In this way it may hence serve as a tool to improve the individualization of 
the long term immunosupression regime.  
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It was difficult to see a clear pattern related to Banff classification based on these data. 
There might, however, be a connection between severity of the rejection and the grade of up-
regulation of the proteins. In the only patient with arterial changes (Banff 2 A) in the biopsy, 
the urine proteins were  highly up- regulated with 10 of the 11 identified proteins elevated at 
the time of AR (the last was not detected). This is also supported by analysis of the samples 
from AR patient 1 (Table 6) which only experienced a borderline rejection. The analysis 
showed a relatively low degree of regulation, where only 4 of the 11 proteins were up-
regulated. 
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Figure 24. Fold change (log2) of immune proteins, growth factors and MEP1A in the 
rejection group, AR1 (●) AR2 (×) AR3 (♦) AR4 (+) AR5 (■) AR6 (▲), from baseline to 
Biopsy Proven Acute Rejection (BPAR). The center point (Clinically stable) is 7-11 days 
before BPAR, at stable serum creatinine levels. 
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All patients in the rejection group were regulated above the predefined threshold in at least 
one of the proteins groups of which no significant regulation was observed in the control 
group. Figure 25 shows a boxplot of the regulated proteins in both groups. The results show 
that the growth factors were statistically significant up-regulated in the rejection group 
compared with the control group (P=0.03).  
ND
p=0.03 p=0.13
 
Figure 25. Boxplot showing fold change (log2) of immune proteins, growth factors and 
MEP1A from baseline to AR in the AR-group compared with the control group 
 
The up-regulated proteins coupled to cell growth are involved in several biological processes. 
Insulin-like growth factor-binding protein 7 (IGFBP7) has shown to modulate effects of 
vascular endothelial growth factor (VEGF) [104] and is reported to interact with chemokines 
of, and act as a marker for activated endothelial cells [105,106]. One of the chemokines, IFN-
γ-inducible protein 10 (IP-10; CXCL10), has also been reported to be elevated in urine during 
AR in kidney transplants [93,97]. Vasorin binds directly to transforming growth factor-beta 
(TGF-β1) [107], previously reported to be involved in the pathogenesis of chronic renal 
allograft dysfunction [108,109]. The encoding gene of galectin-3-binding protein, 
LGALS3BP, is a broadly active immune stimulator associated with several types of immune 
cells [110]. Recently, the protein has been identified as a stimulant of Interleukin-6 (IL-6) 
expression in bone marrow stromal cells [111]. Interestingly, increased urinary levels of IL-6 
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have earlier been reported in association with acute rejection episodes in kidney transplants 
[95,112]. Epidermal growth factor (EGF), or pro-epidermal growth factor, is a large protein 
highly expressed in the kidney and has been reported to be reduced during AR in rats (gene 
expression) and humans (urinary excretion) [112,113].  
For the immune proteins, up-regulation was observed in 4 out of 6 patients during AR 
showing a relatively strong increase of protein levels in the up-regulated patients. The 
immune proteins showed an overall trend of up-regulation in the rejection group, but not 
statistically significant (P=0.13) The 2 remaining patients in the rejection group actually 
showed a slight decrease during AR compared to baseline, mostly because of a strong down-
regulation of acute phase proteins Complement C3 and CD59 glycoprotein in each of the 
patients respectively. CD59 exerts an inhibitory effect on the complement system and 
inclusion in the immune protein group can be discussed since it counteracts the effect of 
several of the other proteins. Interestingly, exclusion of CD59 from this group gives a 
significant difference between the AR and control group (P=0.045). In the control group most 
of the patients showed decreased levels of immune proteins compared to baseline, especially 
for the acute phase proteins where a strong down-regulation was observed in several patients. 
This is a somewhat different picture than from the proteins involved in growth, where the 
levels were relatively stable.  
The proteins categorized in the immune related protein group are mainly acute phase 
proteins, but also proteins involved in antigen and immunoglobulin binding. HLA class II 
histo-compatibility antigen gamma chain (invariant chain or CD74) perform several activities 
affecting T-cells, B-cells and antigen presenting cells within the immune system [114]. The 
pro-inflammatory cytokine Macrophage migration inhibitory factor (MIF), which has a 
number of important immune functions like activation of macrophages and T-cells, is an 
extracellular ligand for CD74 in complex with CD44 [115,116]. MIF plays an important role 
in kidney disease and has been associated with AR in kidney transplants [90]. Mannan-
binding lectin serin protease 2 (MASP2) is a protease that activates complement via the lectin 
pathway [117] and another protein identified as up-regulated, polymeric immunoglobulin 
receptor, has been linked to activation of the lectin pathway in patients with IgA nephropathy 
[118]. Moreover, both complement C3 and CD59 glycoprotein from the complement system 
was elevated during AR. Although the majority of C3 is produced in the liver, various cells of 
the kidney are capable of production and a pathogenic role of C3 during rejection episodes 
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has previously been suggested [119,120]. Ceruloplasmin is also a protein produced by the 
liver during the acute phase of an inflammatory response [121], and was reported to be 
quantitatively up-regulated during AR (pediatric kidney transplants) in the study performed 
by Sigdel et al. [100]. 
MEP1A protein levels were elevated during AR in all patients. The protein was however not 
detected in any of the patients in the control group. Meprins are highly expressed in the 
brush-border membranes of both kidney and intestine and has been associated with acute 
kidney injury in mice [122]. The absence of identified MEP1A in the control group is an 
interesting observation and could potentially be useful in a diagnostic setting. This needs 
however to be investigated more thoroughly to ensure that the observation is not due to 
methodological issues. The peptides related to MEP1A were however identified by the 
proteomic method with a high degree of confidence and all peptides were specific for the 
protein. 
 One major strength of the analysis is that each patient was his or her own control, 
comparing the protein levels during AR with the levels at baseline and individual samples 
were analyzed, not pooled urine. This provides a more detailed pattern of the protein 
regulation activated in association with an acute rejection. All identified proteins are 
physiological plausible to be involved in an acute rejection episode. Since we investigated 
sequential samples it was possible to identify that the activation of these proteins were 
present already more than a week prior to the clinical identification of the acute rejection. A 
limitation of this study is the lack of urine analysis after treatment of acute rejection episodes. 
Logically, a urinary biomarker of potential diagnostic value should return to baseline level as 
the acute rejection episode is successfully treated. Unfortunately these urines were not 
collected in the present trial and it was not possible to show this for the identified proteins in 
the present analysis. It should also be kept in mind that the control group patients were not 
verified non-rejectors by protocol biopsies. Previous studies where biopsies of stable patients 
treated with CsA were analyzed showed an incidence of almost 30 % subclinical rejections 
[123,124]. It is hence possible that subclinical rejections could be present in the control 
group, which in turn could affect the protein regulation in these patient group making the 
interpretation somewhat biased. 
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3.4.3 Comparison with earlier published data 
Regarding earlier reported regulated proteins in urine associated to AR, several of these were 
also detected, but not significantly regulated, in the current study. Sigdel et al. used pooled 
samples and found a list of up- and down-regulated proteins, of which uromodulin, CD44 and 
SERPINF1 was investigated further [100]. The results showed down-regulation of 
uromodulin and CD44 and up-regulation of SERPINF1. Data from the present study of 
individual samples suggest a high degree of between patient variability in the regulation of 
uromodulin in the rejection group, showing highly elevated protein levels in 3 patients and a 
decrease in concentration in 2 of the patients. SERPINF1 did not show any clear regulation 
pattern while CD44 was increased during AR in 4 patients, but only in 1 of the patients was 
the up-regulation more than two-fold. Another study identified β-defensin-1 and α-1-
antichymotrypsin as regulated in AR [125]. The data from Paper V also supports this to some 
extent. No obvious increase was observed during AR in the rejection group, but a distinct 
decrease was seen in the control group indicating a potential regulation of α-1-
antichymotrypsin, even though it did not fulfill the present predefined criteria for regulation 
in the current study. In addition, other proteins have been investigated using a more targeted 
approach (e.g. ELISA) but these could not be supported by the current investigation [90-
99,101]. However, several of these proteins (e.g. MIF, IP-10 and IL-6) are physiologically 
associated with the up-regulated proteins identified in our study as pointed out in section 
3.4.2. 
 
3.5 Future perspectives 
The developed method has shown proof of concept in biomarker discovery of the present set-
up by identifying several urinary proteins associated with acute rejection episodes in kidney 
transplants in this pilot study. Before this can be used in a clinical setting, validation must be 
carried out in a larger population. There are several paths that can be used, but a more 
targeted method monitoring only the proteins of interest is probably necessary to be able to 
analyze the large number of urine samples that such a study would demand. One possible 
approach is antibody mediated clean-up of the proteins using e.g. ELISA perhaps in 
combination with LC-MS/MS. Another technique which could be used is Multiple Reaction 
Monitoring (MRM) of unique peptide products from the proteins of interest. Both of these 
techniques can be carried out without the extensive sample preparation and without the need 
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of multidimensional chromatography, reducing both the workload and time used for each 
sample. 
In order to remove doubt over possible sub-clinical rejections not discovered in the no-
rejection group, the control group should preferably consist of kidney transplanted that are 
confirmed non-rejectors. This could be done by analysis of urine samples at the time of 
protocol biopsies. 
The kinetics of the identified proteins has not been investigated in the present study. This 
would demand analysis of sequential samples from each patient to find the exact timing of 
the increase in protein concentration. Such information could be very valuable from a clinical 
point of view. This would however also demand a large amount of samples and a more 
targeted approach would hence be more appropriate as mentioned above. 
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4 Concluding remarks 
In the presented work a proteomic method has been developed and optimized in order to 
analyze urine from kidney transplanted patients. By applying the developed method several 
proteins potentially associated with acute rejection episodes were successfully identified. The 
biological functions of the identified proteins were mainly related to immune response and 
growth functions. The group of proteins related to growth was significantly up-regulated and 
included the proteins IGFBP7, Vasorin, EGF and Galectin-3-binding protein. For the proteins 
related to immune response, MASP2, C3, CD59, Ceruloplasmin, PiGR and CD74, there was 
a strong tendency towards up-regulation. Up-regulation of both groups tended to appear 
before current diagnostic tools were able set the diagnosis in the patient group. This could 
make the proteins useful in a clinical setting enabling earlier recognition of acute rejection 
episodes in a non-invasive manner. There is however a need for validation of the proteins in a 
larger population and development of a less labor- and time-demanding method. 
 
In the development phase of the method, downstream compatibility was one of the key 
words. The result was a method with a minimal amount of sample handling between each 
step to eliminate possible sources of variability. Several approaches to tryptic digestion of 
proteins were also tested, introducing immobilized trypsin and different technical solutions. 
The format of choice was immobilized trypsin beads which enabled tryptic digestion of 
proteins with the same quality as the standard in-solution digestion, but within a substantially 
shorter timeframe.  
 
A complete on-line method including all steps in a proteomic workflow was also evaluated. 
The results were promising and the potential for automation is very interesting, but the 
method was too premature and not ready for use in biomarker discovery yet. 
  
A significant improvement of the standard tryptic digestion and 18O/16O-labeling procedures 
were accomplished by making an integrated approach utilizing immobilized trypsin beads for 
both steps. The developed method is a time efficient alternative for quantification in urinary 
proteomics by stable isotope labeling. By integrating all procedures keeping the sample in 
one sample reactor, the recovery was improved and the variability reduced. 
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Two-dimensional chromatographic separation of the complex urinary tryptic digest was 
successfully carried out combining HILIC and RP. This yielded a relative orthogonal 
separation of the tryptic peptides increasing greatly the number of peptides detectable. After 
implementation of nanoscale RP separation in the final optimized method, over 1000 proteins 
were identified in one single sample. 
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Abstract 
Acute rejection (AR) impairs renal transplant outcome. Currently acute rejections are 
suspected by a rise in plasma creatinine, and verified by graft biopsy. Identification of non-
invasive biomarkers for AR is an unmet clinical need. The urinary proteome is a promising 
source of relevant biomarkers. From a prospective study, collecting at least weekly urines, we 
extracted samples from twelve renal transplant recipients to be analyzed. Shotgun proteomics 
were used to analyze urine from patients experiencing acute rejections (n=6) in a clinical 
stable phase and at the time of biopsy verified acute rejection. In age-matched control 
patients not experiencing acute rejection (n=6), analyses were performed at comparable time-
points. Eleven up-regulated proteins were associated with AR and they increased several days 
before biopsy proven AR. These proteins could be grouped by biological function in 2 main 
groups: Proteins related to growth (IGFBP7, Vasorin, EGF and Galectin-3-binding protein) 
were significantly up-regulated in the AR-group (P=0.03) and proteins related to immune 
response (MASP2, C3, CD59, Ceruloplasmin, PiGR and CD74) tended to be up-regulated 
(P=0.13). Urinary proteomics provides a robust and sensitive method for identification of 
predictive biomarkers of AR. Further research is needed to establish the clinical role of this 
non-invasive method of AR diagnosis. 
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Introduction 
Patients whom experience an acute rejection (AR) after renal transplantation have reduced 
long-term graft survival and an increased risk of developing chronic allograft nephropathy (1-
5). In a clinical setting an AR is typically suspected upon an increase in plasma creatinine 
that cannot be explained by other plausible causes. Histological examination of renal 
transplant core biopsies is the current gold standard for diagnosis of a suspected rejection (6). 
It suffers from sampling heterogeneity and correlates poorly with treatment response and 
prognosis. The use of plasma creatinine as an indication of acute rejection episodes is flawed 
by both its relatively late response and low specificity.   
Even though renal biopsy per se is considered a relatively safe procedure it is time-
consuming and invasive (7). In the general follow-up of transplanted patients a non-invasive 
method with high sensitivity and specificity for diagnosing AR would be a desirable tool. The 
urinary proteome can be assessed non-invasively and consists of both proteins excreted from 
plasma (30 %) and locally produced in the kidney (70 %) (8, 9). Inflammation associated 
with an AR would change the proteome produced in the transplanted kidney and alter the 
excretion of the proteome from plasma. This makes urine particularly interesting when it 
comes to identification of potential diagnostic biomarkers for kidney transplant dysfunction. 
Several attempts have been made to identify possible urinary biomarkers for AR (10-21), but 
none are used clinically (22, 23). Most of the studies done are hypothesis based and only 
focus on a few specific target proteins. The development in the field of mass spectrometry 
has, however, made screening analysis of the full proteome technically possible. This opens 
for new strategies of biomarker identification in this patient population. Recently, Sigdel et 
al. used shotgun proteomics to identify proteins in pooled urine samples from pediatric 
kidney transplants with acute rejection (20). 
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We performed a small prospective pilot study in order to try to identify urinary proteins 
associated with AR episodes in the early phase following kidney transplantation. Shotgun 
proteomic analysis of prospectively collected urine samples from each individual utilizing the 
LTQ-Orbitrap technology was used. In shotgun proteomics proteins are enzymatically 
digested into peptides which are separated by liquid chromatography coupled to a mass 
spectrometer. The use of tandem mass spectrometry allows for peptide sequencing which is 
then used for protein identification by searching against protein databases. Analysis of 
individual samples gives information on inter-individual variation. Quantification was carried 
out using stable isotope labeling (18O/16O) comparing AR and baseline samples. 
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Materials and methods 
Study design and samples 
We used urine samples from 6 renal transplant patients with biopsy proven acute rejection 
(BPAR) and from 6 renal transplant patients with stable graft function, matched for age, 
immunosuppression and time after transplantation. All urine samples were collected 
prospectively as part of an at that time ongoing study at Oslo University Hospital (n=20) 
(24). On average urine samples were available from 4.7±2.7 days after transplantation and 
the patients were followed for 8-10 weeks. All patients’ received induction with i.v. 
basiliximab on day 0 and 4, cyclosporine A (CsA), mycophenolate mofetil 1 g BID, steroids, 
sulfacotrimoxacole and proton pump inhibitor. Clinical information, blood and urine samples 
were collected during the whole period. Urinary samples were collected three times weekly 
the first two weeks, twice weekly the next four weeks followed by 1-2 samples per week until 
approximately 10 weeks after transplantation. Acute rejections were suspected in patients 
based on an increased plasma creatinine of 20%, without other plausible causes, and were 
verified with a renal core biopsy according to the Banff 97 criteria (6). Urine samples from 
the day of BPAR were compared with the first available urine sample after transplantation 
(baseline) and with a sample from a clinically stable phase, approximately one week prior to 
rejection. Urine samples from the control group were attained at similar time points after 
transplantation. 
The study was performed in accordance with the Declaration of Helsinki and the signed 
informed consent for the main study covered these urinary proteomics analyses. The study 
was evaluated by the Regional Committee for Medical Research Ethics, approved by the 
Norwegian Medicines Agency and registered on www.clinicaltrials.gov (NCT00139009). 
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Urine sample preparation 
Midstream urine were collected several times from each recipient, left at 4 °C for up to one 
hour, centrifuged at 800 × g for 10 minutes and stored at -70 °C.  Further sample preparation 
of urine was performed as previously described (25). In brief: 5 mL of stored urine was 
centrifuged at 9000 × g for 10 minutes and applied to Vivaspin 5 kDa cut-off centrifugal 
filter (Vivascience Sartorius Group, Stonehouse, UK) for desalting and up-concentration of 
urinary proteins, followed by washing and reconstitution (1200 µL) using 10 mM 
TrisHCl/150 mM NaCl (pH 7.4). Total protein concentrations in each sample was measured 
using Bradford’s method (26) and the samples from each patient was normalized with respect 
to total protein content. A volume of 300 µL was transferred to Vivapure Anti-HSA kit 
(Vivascience Sartorius Group) for albumin depletion. Reduction of the proteins was done 
using DTT (1 µg per 50 µg protein) at 95 °C for 15 minutes, followed by alkylation with 
iodoacetic acid (5 µg per 50 µg protein) in the dark at room temperature for 15 min. Tryptic 
digestion and 18O/16O-labeling of the samples was done as described earlier (27). The key 
parameters were as follows: A sample volume of 50 µL was applied to immobilized trypsin 
beads and digested using a pH 8.0 buffer at 37 °C for 90 minutes under shaking (1200 rpm). 
Subsequently, the samples were subjected to 18O/16O-labeling using the same beads, but with 
a different buffer (pH 6.0) at 37 °C for 3 hours under shaking (1200 rpm). Finally, the 
samples were purified and desalted by using in-house produced C18-tips prior to 2D LC-
MS/MS analysis. The AR samples were labeled with 18O and mixed with both unlabeled 
baseline samples and unlabeled stable samples (7-11 days prior to rejection) in the AR-group. 
In the control group, the time matched samples after transplantation was labeled and mixed 
with unlabeled baseline samples. 
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2D LC-MS/MS 
Two-dimensional LC-MS/MS was used for separation and detection of the tryptic digested 
peptide mixture. Hydrophilic Interaction Liquid Chromatography (HILIC) was used as the 
first dimension of separation and was done exactly as described previously (25, 27). Fractions 
were collected every minute, in total 30 fractions per sample. All fractions were evaporated 
on a SpeedVac (Thermo) and reconstituted in 60 µL of 2 % MeCN in 20 mM formic acid. 
The nanoLC-MS/MS analysis was done using 20 µL of reconstituted fractions as primarily as 
described earlier using an Ultimate 3000 HPLC system (Dionex) coupled to a LTQ-Orbitrap-
MS (Thermo, San Jose, CA, USA) (27). The modified HPLC setup in brief: The reconstituted 
fractions were trapped on a C18 5 mm x 300 µm id Acclaim PepMap 100 (5 µm) enrichment 
column (Dionex). The loading mobile phase was 20 mM formic acid and MeCN (98/2, v/v) 
delivered at a flow rate of 10 µL/min for 4 minutes. The sample was transferred to a 150 × 
0.075 mm id Acclaim PepMap 100 (pore size 100 Å and particle diameter 3 µm; Dionex) at a 
flow rate of 300 nL/min (pump flow: 300 µL/mL, split 1:1000 in flow manager). The mobile 
phases consisted of A: 20 mM formic acid and MeCN (95/5, v/v) and B: 20 mM formic acid 
and MeCN (5/95, v/v). A linear gradient was run from 0 % to 50 % B in 60 minutes. 
Subsequently, the elution strength was increased to 100 %. 
The nanospray ionization (NSI) source was operated in the positive ionization mode using a 
360 µm od × 20 µm id distal coated fused silica emitter with a 10 µm id tip (New Objective, 
Woburn, MA, USA). Experiments were performed in two scan events: Scan event 1: scan 
from m/z 300 to m/z 2000 in the FT-Orbitrap with resolution R = 30000. Scan event 2: data 
dependent MS/MS with wide band activation carried out on the highest m/z value for a 
maximum of one spectrum in the linear ion-trap. The m/z values fragmented were 
dynamically excluded for 15 sec in order to fragment lower intensity m/z values. Helium gas 
was used to cause collision-induced fragmentation at 35 % relative collision energy. 
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Identification and selection of proteins 
The acquired mass spectrometric data were analyzed and processed using Proteome 
Discoverer 1.2 (Thermo) software. The raw files were analyzed in 2 search nodes, where the 
first search node was a SEQUEST™ (28) search against the FASTA file ipi.HUMAN.v3.76. 
Carboxymethyl (C) was set as constant modification while oxidation (M) and 18O (2) on the 
C-terminal were chosen as variable modifications. The peptide tolerance was set to 10 ppm 
while MS/MS tolerance was ±0.8 Da and 2 “missed cleavages” were allowed using trypsin as 
enzyme. A decoy database search was performed by searching against a database containing 
the reversed protein sequences with a strict target false discovery rate (FDR) of 0.01 and a 
relaxed FDR of 0.05. Grouping of proteins were enabled and only the top ranked peptide hits 
below the FDR threshold (< 0.05) were accepted. In the second search node precursor ions 
were detected for quantification. The heavy label was set to 18O (2) on the C-terminal, while 
the light channel contained no modifications. Only unique peptides were used for 
quantification and the ratios were normalized against the protein median of the quantified 
proteins in each patient. The results of the 2 search nodes were merged after processing the 
data. 
For all protein and protein groups: up-regulation was defined as a fold change of ≥1 (log 2) in 
protein level observed between baseline and AR. This was calculated by log 2 transforming 
the actual 18O/16O protein ratios (AR/baseline). The list of up-regulated proteins from the 
study (listed in Table 2) was selected based on several criteria where the first was up-
regulation (log 2 change ≥1) from baseline to AR in at least three patients in the rejection 
group. Further, proteins with higher average ratio in the control group and proteins more 
frequently up-regulated in the control group were excluded. 
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Statistics 
For the evaluation of the demographic data and comparison of the groups, the Mann-Whitney 
U test was used. A P-value of <0.05 was considered statistical significant and all analyses 
were performed by Minitab version 16.1 (Minitab Inc., Coventry, UK). 
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Results 
Patient demographics 
Demographic data of the twelve patients, six with acute rejection and six controls, included in 
the present analysis are shown in Table 1. The patients in the AR-group experienced biopsy-
proven acute rejection episodes on average 42±27 days after transplantation. No significant 
differences were present between the AR-group and the non-rejection group with respect to 
recipient age, HLA mismatch or donor age.  
Three urine samples from each patient in the AR-group were analyzed; the first available 
urine sample after transplantation (5.0±3.6 days post transplant, baseline), one sample 
obtained in a clinically stable phase (7-11 days prior to BPAR) and one at the day of BPAR, 
obtained prior to biopsying. Two samples from each patient in the control group were 
analyzed; the first available urine samples post transplant (4.3 1.8 days) and urine from time-
points matched to the time of BPAR in the AR-group.  
 
Up-regulated proteins during AR episodes 
A total of eleven proteins fulfilled the criteria of a regulated protein (Table 2). Ten of the 
proteins could be grouped in two main groups by their biological function; proteins involved 
in regulation of growth and proteins involved in immune responses. One protein, MEP1A, 
did not fit any of these groups and is presented separately. Figure 1 shows a box plot of the 
regulated protein groups in the rejection group and in the controls. At the time of BPAR the 
growth factor proteins were statistically significant up-regulated in the AR-group compared 
with the control group (P=0.03). All patients (except one) in the AR-group were regulated 
above the predefined threshold. During the same time-interval i.e. at time of BPAR there was 
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a clear trend towards up-regulation of the immune response proteins in the AR-group as 
compared with control patients (P=0.13). For the immune response protein group, up-
regulation was observed in 4 out of 6 patients in the AR-group and in none of the control 
patients. MEP1A was not detected in any of the control patients but significantly up-regulated 
in four of the six patients in the AR-group (not detected in the last two patients). Figure 2 
shows the log 2 changes in protein levels for the specified protein groups between baseline 
and the time of BPAR in the AR-group. The trend is that these regulated proteins are up-
regulated already in a clinically stable phase, 7-11 days prior to the time of BPAR, when 
plasma creatinine still is not elevated. 
 
Discussion 
The present analysis identifies several up-regulated urinary proteins in association with acute 
rejection episodes in the early post transplant phase after kidney transplantation. The results 
demonstrate the applicability of combining shotgun proteomics with quantification by 
18O/16O-labeling in biomarker discovery using sequential samples from several patients. By 
comparing baseline and event samples in the two groups each patient serve as its own control. 
This approach, as compared to the more commonly used pooled sample strategy, gives a 
more informative picture since inter-individual variability can be assessed.  The present 
finding of specific up-regulation of several protein biomarkers in urine may provide a non-
invasive and effective way to diagnose acute rejection episodes following renal 
transplantation. 
A very interesting and important finding of this sequential analysis is that the up-regulation 
was detected already several days prior to the acute rejection was clinically suspected based 
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on the currently used methods. Any rejection is an on-going process and it is well known that 
it may take time before a substantial increase in plasma creatinine (>20%) evolves, and an 
acute rejection is suspected. If the altered urine proteome turns out to be an earlier responding 
and more specific biomarker of acute rejection it could have dramatic implications on long 
term outcome of renal transplant recipients. It is possible that only a minor adjustment of the 
immunosuppressive therapy would be enough to “silence” the early activated immune 
process, and with this avoid full activation of the immune system. Sequential urine proteomic 
analysis could possibly also serve as an “immunometer” during tapering of the initial high 
immunosuppressive load after engraftment. In this way it may hence serve as a 
complimentary tool to standard therapeutic drug monitoring and further improve the 
individualization of the long-term immunosuppressive regime.    
Only the Mannan-binding lectin serin protease 2 (MASP2) was up-regulated in all patients 
with AR. The extent of regulation of each protein differed individually as showed in Table 2, 
without any obvious pattern. Grouping the proteins by biological functions substantiated a 
potentially relevant regulation in the rejection group of the other identified proteins as 
compared with the control group.  There might however be a connection between severity of 
the acute rejection and the grade of up-regulation of the proteins. In the only patient with 
arterial changes (Banff 2 A) in the biopsy the regulated urine proteins were almost 
universally up- regulated, with 10 of the 11 identified proteins elevated at the time of AR (the 
last was not detected). Analysis of the samples from AR patient 1 (Table 2) which only 
experienced a borderline rejection further supports this hypothesis as only a relatively low 
degree of regulation was seen; only 4 of the 11 proteins were up-regulated.  
For the proteins related to immune response, a strong up-regulation was observed at the time 
of rejection in 4 of the patients in the AR-group. The 2 remaining patients, one of the patients 
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with only a borderline rejection, as mentioned above, actually showed a slight down 
regulation of these proteins during AR compared to baseline. This was mostly because of a 
strong down-regulation of acute phase proteins Complement C3 and CD59 glycoprotein in 
each of these two patients, respectively. CD59 exerts an inhibitory effect on the complement 
system and inclusion in the immune protein group can be discussed since it counteracts the 
effect of several of the other proteins. Interestingly, exclusion of CD59 from this protein 
group results in a significant difference between the AR and control group (P=0.045). In the 
control group most of the patients showed decreased levels of immune proteins compared to 
baseline, especially for the acute phase proteins where a strong down-regulation was 
observed in several patients. This is a somewhat different picture than from the proteins 
involved in growth, where the levels were relatively stable. The proteins categorized in this 
group are mainly acute phase proteins, but also proteins involved in antigen and 
immunoglobulin binding. 
Earlier studies have shown data which may support a relevant contribution of many of these 
proteins in acute rejection episodes. For example, the pro-inflammatory cytokine Macrophage 
migration inhibitory factor (MIF) which is an extracellular ligand for CD74 (29, 30), has been 
associated with AR in kidney transplants (10). MASP2, polymeric immunoglobulin receptor, 
Ceruloplasmin and participants in the complement system have also been shown to be 
regulated in association with acute rejection (20, 31-36). 
The proteins involved in cell growth were up-regulated in 5 of 6 patients in the AR-group and 
are involved in several biological processes relevant to acute rejection episodes. Insulin-like 
growth factor-binding protein 7 (IGFBP7) modulate effects of vascular endothelial growth 
factor (VEGF) (37) and is reported to interact with chemokines in high endothelial venules 
including IFN-γ-inducible protein 10 (IP-10; CXCL10) (38, 39), which has previously been 
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reported to be elevated in urine in connection with AR (13, 17). Vasorin and Galectin-3-
binding protein are closely associated to transforming growth factor-beta (TGF-β1) and IL-6, 
both previously linked to acute rejection in this patient population (15, 40-45). 
Meprin A subunit alpha (MEP1A protein) did not fit to either of the two protein groups and 
was only detected in the AR-group. In AR patients the protein levels were significantly 
higher at the time of AR compared to baseline. Meprins are highly expressed in the brush-
border membranes of both kidney and intestine and has been associated with acute kidney 
injury in mice (46). The absence of identified MEP1A in the control group is an interesting 
observation and could potentially be very useful in a diagnostic setting. This should however 
be investigated thoroughly to ensure that the observation is not due to unspecific renal injury 
or methodological issues. The peptides related to MEP1A were however identified by the 
proteomic method with a high degree of confidence and all peptides were specific for this 
protein.  
Regarding earlier reports of proteins regulated in urine in association with acute rejections; 
several of these were also detected in our study but not significantly regulated. When 
comparing results from pooled samples taken from patients with acute rejection and samples 
taken from stable patients Sigdel et al. found several up- and down-regulated proteins. They 
performed further investigations an found a down-regulation of uromodulin and CD44 and 
up-regulation of SERPINF1 (20). Data from the present study of individual samples suggest a 
high degree of between patient variability in the regulation of uromodulin in the rejection 
group, showing highly elevated protein levels in 3 patients and a decrease in concentration in 
2 of the patients. SERPINF1 did not show any clear regulation pattern while CD44 was 
slightly increased during AR in 4 patients, but the increase was less than twofold in all except 
one patient i.e. not enough to serve as a reliable rejection marker according to our criteria. 
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Another study identified β-defensin-1 and α-1-antichymotrypsin as regulated during acute 
rejection (47). Our data also supports this to some extent. No obvious increase was, however, 
observed during rejection in the AR-group, but a distinct decrease was seen in the control 
group indicating a potential regulation of α-1-antichymotrypsin, even though it did not fulfill 
our predefined criteria for regulation. In addition, other proteins have been investigated using 
a more targeted approach (e.g. ELISA) but these were not confirmed by our investigation 
(10-19, 21). However, several of these proteins (e.g. MIF, IP-10 and IL-6) are physiologically 
associated with the up-regulated proteins identified in the present study. 
A major strength of our analysis is that each patient was his or her own control, comparing 
the protein levels during AR with the levels at periods without rejection. In addition  
individual samples were analyzed in the present study, not pooled urine. This provides more 
detailed information of the protein regulation in association with an acute rejection. All 
identified proteins are also physiological plausible to be involved in an acute rejection 
episode, further substantiating our findings. Since we investigated sequential samples it was 
possible to identify that the activation of these proteins were present already several days 
before clinical suspicion of the acute rejections were present. A limitation of the present 
study is the lack of urine analysis after treatment of the acute rejection episodes. Logically, a 
urinary biomarker of potential diagnostic value should return to baseline level as the acute 
rejection episode is successfully reversed. Unfortunately, relevant urines for such analyses 
were not collected in the present trial. It should also be pointed out that the control group 
patients were not verified non-rejectors by protocol biopsies. Previous studies have shown an 
incidence of almost 30 % subclinical rejections in apparently stable patients treated with CsA 
(48, 49). It is hence possible that sub-clinical rejections could be present in some of the 
control patients. This would affect the protein regulation in this patient group, making the 
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interpretation somewhat biased. In addition, the present analysis only includes a very 
restricted number of patients. Further prospective studies are therefore needed in larger 
populations, where biopsies also are performed in the control patients, in order to elucidate on 
the involvement of these proteins in acute rejection and their potential usability as diagnostic 
biomarkers. 
In conclusion, this study shows the applicability of shotgun proteomics in combination with 
quantification by 18O/16O-labeling in biomarker discovery in sequential urine samples. Two 
groups of physiological related proteins with relevance to immunological processes during 
acute rejection episodes were found to be elevated in patients with BPAR compared to 
controls. The use of urine and a trend towards an increase of proteins levels prior to 
deterioration of graft function potentially opens for early, specific and non-invasive detection 
of acute rejection episodes. Prevention of acute rejections, rather than cure, could 
dramatically improve long term graft survival.
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Tables 
Table 1. Demographic data 
 All No-rejection group Rejection group P value 
Gender (male/female) 7/5 3/3 4/2  
Weight (kg) 75.7±10.2 80.2±11.1 71.3±7.7 0.09 
Age (years) 55.0±12.2 59.5±5.4 50.5±15.8 0.26 
HLA mismatch (A + B) 1.2±0.9 1.0±1.1 1.3±0.8 0.47 
HLA mismatch (DR) 1.2±0.7 1.2±0.8 1.2±0.8 1.00 
HLA mismatch (DQ) 0.5±0.5 0.4±0.5 0.5±0.5 0.86 
Serum creatinine* 143±48 119±55 168±24 0.07 
Age donor (years) 51.5±10.8 49.0±14.8 54.0±4.6 0.52 
Deceased donor (n) 11/12 6/6 5/6  
Data are means±SD 
*at time of BPAR and matched time-points, 
respectively 
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Legend to figures 
Figure 1. Box plot showing fold change (log2) of immune proteins, growth factors and 
MEP1A from baseline to acute rejection in the AR-group compared with the control group. 
 
Figure 2. Fold change (log2) of immune proteins, growth factors and MEP1A in the rejection 
group, AR1 (●) AR2 (×) AR3 (♦) AR4 (+) AR5 (■) AR6 (▲), from baseline to Biopsy 
Proven Acute Rejection (BPAR). The center point (Clinically stable) is 7-11 days before 
BPAR, at stable serum creatinine levels. 
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